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The voltage-gated sodium (Nav) channel complex is comprised of a 
channel-forming, ion-conducting α-subunit and one or multiple accessory β-
subunits. The latter has been shown to influence the function of Nav channels 
and mutations within the β-subunit have been tied to cardiac and neurologic 
disorders. We show here that β-subunits can also affect the pharmacology of 
Nav channels, particularly in relation to toxins derived from animal venoms. In 
this work we combine our knowledge of toxin binding sites with novel crystal 
structures of two β-subunits to determine the cysteine residues responsible for 
forming the disulfide bridge between the β2/β4 subunits and the Nav1.2 channel. 
In doing so, we provide a basis for understanding the interaction between the β-
subunits and Nav channels and the functional consequences of this interaction. 
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ARCHITECTURE OF THE BETA2/BETA4-NAV CHANNEL  
SIGNALING COMPLEX  




The voltage-gated sodium channel signaling complex 
The voltage-gated sodium (Nav) channel signaling complex is a critical 
component of electrical signaling within the body. As the Nav complex is 
responsible for axonal nerve conduction, initiation of the (cardiac) action 
potential, and a host of other roles, the importance of the Nav complex is 
reflected in the number of diseases resulting from or associated with mutations of 
its constituents [1]. These diseases range from neurologic syndromes like 
epilepsy [2] and migraine [3] to cardiac disorders such as Brugada syndrome [4] 
and Long QT syndrome [5] and even extreme pain [6] or total insensitivity to pain 
[7]. Despite the long history of Nav channel research, only in the past two 
decades has the role of auxiliary subunits come to light, illuminating their ability 
to modify channel gating as well as other Nav channel-independent roles [8-10]. 
The Nav complex is composed of several integral membrane proteins [11], 
including the pore-forming α-subunit (the Nav channel) and the auxiliary β-
subunit. A description of each follows. 




The voltage-gated sodium (Nav) channel (α-subunit, referred to henceforth 
as the Nav channel) is a transmembrane glycoprotein with 24 transmembrane 
(TM) segments, organized into four domains with six TM segments each, with the 
first four TM segments comprising the voltage-sensor and the latter two 
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contributing to the formation of the central ion-conducting pore. The pore is a 
cavity within the center of the Nav channel α-subunit circumscribed by eight TM 
helices with each domain contributing two helices [12] (Fig. 1-1). Within the pore, 
a selectivity filter formed by an Asp-Glu-Lys-Ala (DEKA) motif dictates specificity 
for Na+ over K+ [13-15]. 
The fourth TM segment (S4) of each voltage-sensing domain (VSD) 
carries a number of positive charges, borne on the basic side chains of Arg and 
Lys contained in the S4 [16, 17]. These basic side chains, termed gating 
charges, provide the voltage sensor with its ability to sense voltage, migrating 
through the membrane in response to a change in the electric field [18, 19].   
Both the N- and C-termini reside inside the cell, and the channel spans 
roughly 1900 amino acids between them [20], resulting in a molecular mass of  
approximately 280 kDa, contributed by both the peptide and its glycosylation [21-
23]. The Nav1 family is populated by the related isoforms Nav1.1 through 
Nav1.9, as well as the distantly related Nax [24]. While their discovery was aided 
by the potent Nav-specific blocker tetrodotoxin (TTX) [25, 26], three of the 
isoforms are resistant to this toxin: the cardiac isoform Nav1.5 is somewhat 
resistant [27], while the peripheral nervous system (PNS) isoforms Nav1.8 and 
Nav1.9 are highly resistant [28]. All isoforms are believed to conform to the same 
structural archetype, with very similar TM segments, particularly those of the 
voltage sensor, while the extra- and intracellular loops are highly variable, 
differing in both sequence and length [29].  
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 One of the defining features of Nav channels, and one critical to proper 
function, is their characteristic fast inactivation process, where the activated 
channel terminates its sodium conductance and becomes refractory to 
subsequent depolarizations. While not unique to Nav channels, the inactivation 
process is found in all Nav isoforms [30]. Inactivation has been linked to 
activation of the slower-moving domain IV (DIV) voltage sensor [31-36]. The 
intracellular III-IV linker provides the termed “inactivation gate”, which uses an 
Ile-Phe-Met (IFM) motif presumably to occlude the pore and prevent further Na+ 
flux [37-41]. Subsequent to inactivation, the Nav channel is refractory to 
activation and cannot be opened until after a hyperpolarization event [42]. This 
refractory period is critical for unidirectional conduction of an action potential 
along the axon, preventing a return of depolarization “upstream” from which the 
action potential originated. DI-III are primarily tied to opening; VSDI-III, which are 
believed to move first in response to membrane depolarization, migrate in the 
membrane, driven by the charged S4 helix and opening the channel [18, 31, 33].  
As the Nav channel family is related of the the voltage-gated potassium 
(Kv) channel family, early structural insights into Kv structures were a boon to the 
Nav channel field. Like the Nav channel, the Kv channel also has a central pore 
and four voltage-sensing domains but instead of being formed from a single 
polypeptide chain, the complete Kv channel is a homotetramer of smaller 
subunits that each bear 6 TM domains [43, 44]. As a result, the Kv and Nav 
channels adopt a similar geometry, but the latter exhibits substantial 
heterogeneity between domains [29]. The crystal structures of the KvAP [44] and 
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Kv1.2 [43] channels (2003 and 2005, respectively), propelled many new insights 
into ion channel structure and function. Between then and 2011, when the first 
prokaryotic Nav channel was crystallized [16], the Kv channel served as primary 
structural model for much of what was understood about Nav channel structure. 
Multiple bacterial Nav channel structures were solved [16, 17, 45, 46], but as 
homotetramers themselves, they provided only an incremental improvement on 
the Kv channel. While many new insights were gained, the structure of the 
mammalian Nav channel remained elusive. It was not until 2017 that a eukaryotic 
Nav channel structure was revealed by cryo-EM [47], providing a first glance into 
the channel’s actual pseudoheterotetramer tertiary structure. 
While unique insights into the Nav channel were afforded by the cryo-EM 
structure, much of what was observed in these studies was a confirmation of 
what had been anticipated from the Kv channel. One of the more interesting 
revelations from the Kv channel structure was of the “domain-swap” architecture 
[44, 48, 49], where the two pore-forming segments S5 and S6 sit not next to S1-4 
of the voltage-sensor but instead by the VSD of the retrograde domain. The 
domains are oriented in a clockwise fashion and the domain swap arrangement 
has the pore domain of DIV sitting by VSDIII, and the DIII pore domain by the DII 
voltage-sensor, etc. This same configuration was observed in the bacterial Nav 
channels, highlighting a degree of structural conservation between the voltage-









Found throughout the body on in nerves and muscles, the Nav channel is 
responsible for rapid depolarizations of the cellular membrane, generated by the 
influx of Na+ from outside the cell through the channel [12, 50]. In response to 
small depolarizations of the cell or a rising resting membrane potential, the Nav 
channel activates and by creating a permeability to Na+, quickly shifts the 
membrane potential (Vm) nearer to that of the Na+ Nernst potential, typically 
around +60 mV. The elevation of Vm in the local area can induce other Nav 
channels to open, propagating an action potential down the length of a neuronal 
axon, or it might stimulate voltage-gated calcium (Cav) channels to open, 
triggering muscle contraction or neurotransmitter release. The Nav channels’ 
involvement in neuronal signaling, muscle contraction, and pain makes them 
ideal targets for drug classes including antiepileptics, antiarrhythmics, and 
anaesthetics [51]. Outside of the β-subunits, Nav channels have also been 
observed to interact with other proteins within the cell, such as calmodulin [52], 
contactin [53], ankyrin [54], and several fibroblast growth factor homologous 
factors [55].  
 In the brain, the primary neuronal Nav isoforms found are Nav1.1, Nav1.2, 
and Nav1.6, as well as Nav1.3 to a lesser extent. Nav1.3 is primarily expressed 
embryonically, although it is still present in adult nervous tissue [56]. Sodium 
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channel distribution is complicated, however, and these proteins are subject to 
spatial and temporal regulation [57-59]. Nav1.1 was recently revealed to have a 
role in peripheral pain sensation [60], consistent with its detection in the PNS, 
albeit at low levels. Nav1.6 has been found in the brain, spinal cord, and PNS 
[61-63], primarily at the axon initial segments, somata, and nodes of Ranvier. It is 
thought to be a major component of persistent and resurgent current within 
Purkinje cells [64]. 
Nav1.4 and Nav1.5 are the principal isoforms found in skeletal and cardiac 
muscle, respectively. Nav1.4 is found on skeletal muscle fibers, responding to 
nerve stimulation to initiate excitation-contraction coupling [20, 65, 66]. Nav1.5 is 
required for the initial depolarization of the action potential of cardiac myocytes, 
and is also responsible for conduction of action potentials through the heart. This 
Nav channel is also unique in that it is moderately TTX-resistant [67]. 
The primary PNS isoforms Nav1.7, Nav1.8, and Nav1.9 [68-70] are largely 
associated with their roles in pain sensation. The Nav1.7 subunit is found in 
nociceptive neurons of the dorsal root ganglia (DRG) and sympathetic neurons, 
as well as olfactory neurons and trigeminal ganglia [71]. Generally clustered at 
nerve termini, Nav1.7 serves to amplify small depolarizations, setting the 
threshold for action potential initiation or neurotransmitter secretion [72]. Nav1.8 
and Nav1.9 are also heavily involved in nociception and while being the most 
distantly related to other Nav isoforms they, like other isoforms, are also 
susceptible to modulation by animal toxins [73].  
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Nav channels have also been found to play roles in tissues or cells 
traditionally regarded as unexcitable. In the immune system, for example, Nav1.7 
has been postulated to establish a resting Vm in dendritic cells, tuning them for 
proper activation in response to antigens [74]. Nav1.5, on the other hand, has 
been suggested to play multiple roles: in developing T-cells, the channel is 
essential for activation during positive selection of T-lymphocytes [75] whereas in 
macrophages the channel resides in lysosomes, possibly enabling more 
extensive acidification of the degradative lumen [76]. Nav1.1 and Nav1.6 have 
been found to play multiple roles in mouse microglial cells [77]. 
Given the importance of Nav channels in nervous system and muscle 
control it is unsurprising they are a primary target for animal toxins. Spiders, 
scorpions, and other venomous animals use toxins specific for ion channels to 
incapacitate and kill prey, or protect themselves from predation. Venoms contain 
components targeting many ion channels and hundreds of millions of years of 
evolution have provided researchers with tools to very specifically activate or 
inhibit ion channels, discriminating between ion channel subtypes, even between 
Nav isoforms [78]. Toxins are able to modify Nav channel function through two 
primary mechanisms: pore blockade to directly impair Na+ conductance and 
gating modification, through binding to voltage sensors, to shape the gating 
properties of the cell [78-80].  
 It is difficult to overstate the importance of animal toxins in Nav channel 
research. The first isolations of the Nav channel were done with the neurotoxins 
TTX and LqTx [25, 81, 82], and subsequent mapping of the extracellular topology 
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was done with the aid of LqTxV [83, 84]. The blocker TTX is routinely used to 
eliminate Na+ conductances through subtraction in electrophysiological 
recordings of Nav channels and combinations of Nav isoform-specific animal 





 Considering the roles of Nav channels in normal physiology, it is to be 
expected that most diseases related to them affect the nervous or muscular 
systems. While the disease mechanisms of pathogenic Nav channel mutations 
can be difficult to untangle in neurologic disorders [88], such as epileptic 
syndromes, the pathogenesis is often much better understood in cardiac or 
skeletal muscles disorders [89, 90]. The severity of Nav-related disorders varies, 
as some pose no serious risks to patients while others are frequently disabling or 
even fatal. Generally, the more severe mutations manifest in systems less robust 
to mutation [91].  
 Among the most prevalent and visible Nav channel disorders are the 
various epileptic syndromes arising from mutations in Nav1.1 and Nav1.2 [2, 88, 
92, 93]. Both isoforms have been implicated in epilepsy, but it is the Nav1.1 
isoform that has been most extensively linked to epilepsy [2, 88, 94, 95] and is 
thus a major target in neurologic pharmacy [96]. Nav1.3 and Nav1.6, which are 
also found in the adult CNS, have been linked to epilepsy [97, 98]. The 
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mechanism by which these mutations drive epilepsy is still unclear but is believed 
to involve reduced activity of inhibitory neurons [99-101]. In addition, a mutant 
form of an Nav channel found in the brain, Nav1.6, was found to be involved in 
cerebellar ataxia in mice [102]. 
 The chief Nav isoform expressed in skeletal muscle, Nav1.4, has been 
linked to several myotonic and paralytic conditions [103, 104], defects of 
increased and decreased electrical excitability, respectively. Mutations in this 
channel frequently affect the III-IV linker, impairing fast inactivation and leading to 
aberrant contractility of the muscle cell [105, 106]. In the heart, the cardiac 
isoform Nav1.5 is responsible for initiation of the cardiac action potential and 
mutations within this isoform predictably lead to cardiac disorders [107]. 
Mutations can affect the channel by impairing cardiac conduction [108, 109] or 
arrhythmias [110-112] culminating in a descent into ventricular fibrillation and 
death. Idiopathic ventricular fibrillation syndromes can result from Nav1.5 
mutations, such as Brugada syndrome [113-115] or Sudden Unexplained Death 
Syndrome (SUDS) [116-119].  
Perhaps the most debilitating Nav channel disorders are a result of their 
role in pain signaling, as mutations in Nav1.7, Nav1.8, and Nav1.9 have been 
shown to alternatively lead to heightened pain sensation or complete insensitivity 
to pain. Mutations of Nav1.7 [120, 121] and Nav1.9 [7, 122] have both been 
linked to an insensitivity to pain. To anyone who has broken a bone or even 
stubbed a toe, a lack of pain sensation would seem a blessing, but these 
conditions can in fact be dangerous to their sufferers. As children, patients 
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suffering from this condition suffer frequent chewing-induced damage to fingers 
and tongues, and unwitting burns are common [123]. Curiously, in those lacking 
a functional Nav1.7 isoform, many patients lose their sense of smell in addition to 
that of pain, arising from a role for Nav1.7 in olfactory nerve conduction [124].  
On the other side of the spectrum, mutations in Nav1.7 [6, 125], Nav1.8 
[126], and recently Nav1.9 [127, 128] can lead to hyperactive pain sensations, 
the former contributing to erythromelalgia, in which the burning sensation 
experienced in their extremities has earned the moniker “Man on Fire” syndrome 
[129]. As such, Nav1.7 has become one of the most pharmaceutically relevant 
Nav channel isoforms, and specific modulators of Nav1.7 are some of the most 
sought after compounds in drug research [130]. Nav1.8 has been found to be 
important in chronic and inflammatory pain [131-134]. Other channels have also 
been shown to play a role in pain. The Nav1.3 isoform, typically expressed during 
embryonic development, displays upregulation in injured nerves and contributes 
to neuropathic pain under those circumstances [135, 136]. The neuronal isoform 
Nav1.1, which has been heavily implicated in epilepsy, has also recently been 
shown to play a role in mechanical allodynia [60], offering a new life for 
established Nav1.1-specific antiepileptic drugs in pain modulation [96].  
 Within the Nav signaling complex, the Nav channel appears to be the 
heavy lifter; it senses voltage changes, passes Na+ ions, and is targeted by 
gating-modifier toxins and thus it seems reasonable that disease mutations 
would primarily manifest in the Nav channel itself. However, the β-subunit plays a 
critical role in modifying channel gating and properly localizing the Nav channel, 
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The β-subunit is a single-pass transmembrane protein of approximately 
230 amino acids and a peptide molecular weight about 28 kDa, with an 
extracellular N-terminal domain and a short C-terminal tail inside the cell. The 
extracellular domain adopts an immunoglobulin-like V-type fold [10, 137]. Of the 
four β-subunit isoforms (β1-4), encoded by the genes SCN1B-SCN4B [138-142], 
the internal disulfide is conserved in all of them, but two (β2 and β4) share a 
conserved cysteine that is presumed to be free. The β2 and β4 subunits are 
believed to bind covalently to the Nav channel with a disulfide bridge formed in 
part by this free cysteine (55Cys in β2, 58Cys in β4) [22, 142-145]. The other two 
β-subunits, β1 and β3, are thought to interact with the Nav channel non-
covalently [9, 21, 143, 146-149]. While it is not known where the β2/β4 bind to 
the channel, β1 is believed to interact with VSDIV, explaining some of its 
functional effects on channel inactivation [150, 151].  
 Like the Nav channel α-subunit, the β-subunits are glycosylated and 
several putative N-linked glycosylation sites have been identified [152]. Some of 
these glycosylation sites are thought to have their sugar moieties capped with 
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sialic acid, which has been suggested to play a role in β1 and β2 modification of 
channel gating [153, 154]. At the present time, knowledge of the extent and 
composition of β-subunit glycosylation is limited and the role it plays in β-subunit 
function or folding is uncertain. 
 Knowledge of the three-dimensional structure of the β-subunit is limited, 
but the β1 extracellular domain has been placed by the DI and DIV pore loops 
through cross-linking studies [150, 151] as well as scorpion toxin assays [155]. 
Knowledge of β-subunit function has outpaced that of structure, but structural 




As a subunit of the Nav channel signaling complex, the most prominent 
effects of the β-subunit are on Nav channel gating [8] and in this way to alter the 
electrical aspects of the cell [8, 145, 156-158]. The β1 subunit is the most 
pronounced in this regard, having been shown to affect the kinetics of fast 
inactivation as well as the voltage sensitivity of the channel [151, 152, 159-161], 
the former suggesting an interaction with the Nav channel DIV [150, 151, 162]. In 
addition, β-subunits have been shown to play a role in cell adhesion and 
migration [163]. 
The literature has been divided on the way β1 affects the channel; some 
reports suggest the extracellular domain is responsible for mediating functional 
effects while others purport it is instead the cytoplasmic tail that does so, and 
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some researchers argue both [152, 164, 165]. Regardless, β1 is regarded as the 
most functionally relevant of the β-subunits, being the best characterized 
biophysically and seemingly with the most substantial gating effects, namely a 
hyperpolarizing shift in steady-state inactivation, and an increase in the rate of 
both fast inactivation and recovery from fast inactivation [138]. It is found 
throughout the body, in the brain, spinal cord, heart, and skeletal muscle [138]. 
β1 KO mice show lengthened QT intervals, indicating a critical role in the heart 
[166]. Curiously, despite its significant functional effect in heterologous systems, 
β1 appears to have more subtle effects in vivo and the β1 KO mouse is still 
viable [167]. Presently alone amongst the β-subunits, β1 has an alternatively 
spliced β1b isoform, consisting solely of the extracellular domain of the protein 
[168]. The β1b is believed to be secreted by the cell [141]. 
 The β2 subunit, through its covalent linkage to the channel, appears to 
play a role in modulating currents in DRG neurons, possibly by controlling the 
assembly and trafficking of the Nav channel signaling complex [169]. Generally, 
this subunit is found in brain and spinal cord [139] although others have found it 
in the heart as well [170]. Research has shown a role for glycosylation-mediated 
gating effects of β2 on the cardiac Nav1.5 [153, 154]. SCN2B KO mice are 
generally healthy, beyond a few seizures [171]. While it is believed β2’s effect is 
mediated through stabilization of the Nav channel complex at the cell surface, 
this effect appears cell-type specific and is inconsistent in vivo [172]. 
β3 remains perhaps the least appreciated of the β-subunits, and although 
its role is still uncertain, β3 may behave similarly to β1. Like β1, β3 causes a 
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leftward shift in steady-state inactivation, and accelerates both the rate of fast 
inactivation as well as the recovery from fast inactivation [140]. Multiple reports 
have reported shifts in the conductance-voltage (G-V) and steady-state 
inactivation (SSI) curves of co-expressed Nav channels [158, 173], reflecting 
roles in activation and inactivation, respectively, but reports are often 
contradictory and can vary depending upon the expression system [174, 175]. 
The β3 subunit has been found throughout the body, in the brain, heart, and 
kidney [140] as well as in DRGs [176]. Like β2 KO mice, β3 KO mice are typically 
healthy, but do display some cardiac arrhythmias, suggesting a role for β3 in 
modifying the gating of a cardiac Nav channel [177, 178].  
Possibly the most unconventional subunit, β4 has been implicated in 
several cardiac disorders and appears to play an important role in normal heart 
function. Whether this effect is mediated through a change in gating remains 
uncertain; initial characterizations of the channel suggested the β4 could impart a 
very minor shift in voltage-sensitivity [142]. Apparently unique to β4 is its ability to 
endow a resurgent current onto the Nav channel, allowing the channel to 
reactivate during a timeframe when it would normally be inactivated, enabling 
high frequency firing [179]. The mechanism by which this occurs is still unclear 
but is believed to involve the cytoplasmic tail of β4 interfacing with the internal 
pore of the Nav channel. The β4 cytoplasmic tail is also targeted by secretase 
enzymes, similar to β2 but not seen for β1 or β3, suggesting a possible role for 
β4 in Alzheimer’s [180]. The β4 subunit also plays a role alongside Nav1.5 in a 
cell with a presumably non-excitable membrane -- the developing lymphocyte. 
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During T-cell positive selection in the thymus, β4 was shown to be essential for 
proper production of CD4+ T-cells [75], and has also been seen to be expressed 
during some stages of B-cell development in bone marrow. Clearly, the functional 
roles of β-subunits extend well beyond the nervous system, and even 
independent of Nav channels. Widespread in tissues, β4 is found in brain, spinal 
cord, DRGs, skeletal muscle, and the heart [142]. Thus far a viable β4 KO mouse 
has not been successfully produced, as these mice present a phenotype of 
sudden unexpected death, perhaps mimicking the effect of β4 mutations in the 
heart [181].   
Outside their role in the Nav channel complex, several β-subunits have 
been found to have roles in cell adhesion [8]. Sequence comparisons to the cell-
adhesion molecule myelin protein zero reinforce these findings [139, 140, 152]. 
Aligned with this role in cell adhesion, several of the β-subunits demonstrate 
interactions with structural and cytoskeletal elements such as contactin [182], 
tenascin [183], and ankyrin [184, 185]. In some cases, the β-subunits have been 
revealed to participate in cis- or trans-homophilic or heterophilic engagements 




 Considering their role supporting the Nav channel it comes as no surprise 
that many β-subunit mutations give rise to the same kinds of disease as do 
mutations in Nav channels. The β1 isoform is heavily implicated in epilepsy and 
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the β1 C121W mutation was in fact the first β-subunit mutation to be linked to a 
disease, in this case generalized epilepsy febrile seizures plus (GEFS+) [188], 
with which the R125L mutation is also associated [189]. Other mutants have 
been linked to Dravet syndrome [190, 191], atrial fibrillation [192], and Brugada 
syndrome [193], possibly as a result of their interaction with the neuronal Nav 
channel isoforms Nav1.1 and Nav1.2.  
 While the β2 subunit KO mouse is nonlethal and generally healthy [171], 
the appearance of mild seizures indicates the channel plays some role in the 
brain, though whether this is by directing modulating channel gating or by altering 
localization remains to be seen. Like Nav channels, β2 is also suggested to play 
a part in neuropathic pain [169]. Curiously, the β2 subunit is a target of 
amyloidogneic secretase enzymes, hinting at a potential role in Alzheimer’s 
disease [194, 195]. However, most disease mutations are found near the 
transmembrane region or within the signal peptide, suggesting that the disease 
mechanism may result from a misfolding or mistargeting of the protein [196-200]. 
 Mutations in β3 are suggested to play a role in cardiac arrhythmias [201] 
and Brugada syndrome [202, 203]. However, several mutations in β3 have been 
found in the amino terminus, suggesting their pathogenesis is derived not from 
gating modifications of the Nav1.5 channel but instead by the absence of β3 
subunits [204]. Whether this impacts the function of trafficking of the channel is 
not yet known.   
Given the diverse roles β4 plays throughout the body, diseases arising 
from its malfunction are varied. Thus far, the β4 subunit has been implicated in 
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atrial fibrillation [196], long-QT syndrome (LQTS) [197], and LQTS-associated 
Sudden Infant Death Syndrome [198]. Additionally, evidence has suggested a 
role in Huntington’s disease [205] and, as a result of its targeting by β- and γ-
secretase enzymes similar to β2, Alzheimer’s disease [180].  
 Unfortunately, for many of the diseases in which β-subunit mutations play 
a participatory role, the mechanism remains unclear. The functional 
consequences of Nav channel mutants are often more obvious and easily 
assessed, but the β-subunits exert their effects subtly and mechanisms can be 
more difficult to decipher. Knowledge of Nav channel structure has greatly aided 
the interpretation of mutations and their predicted outcomes, but the paucity of β-
subunit structural knowledge has greatly hindered our knowledge of 
pathogenesis. Hopefully, insights into the β-subunit structures, in conjunction with 
those of the Nav channel structure, will enable a deeper understanding of the 







Figure 1-1: A general depiction of the Nav channel. The central pore of the 
channel is defined by the eight TM segments that delineate it, two (S5 and S6) 
from each domain. The voltage sensors are organized in clockwise fashion while 
the two pore-lining segments of each domain are located adjacent to the 
preceding voltage sensor. A dashed circle indicates the segments (S1-S4) that 





ARCHITECTURE OF THE BETA2/BETA4-NAV CHANNEL  
SIGNALING COMPLEX  
Chapter 2:  Crystallographic insights into sodium-channel modulation by the β4 
subunit 
 
This chapter adapted from: 
Gilchrist, J., et al., Crystallographic insights into sodium-channel modulation by 
the β4 subunit. Proceedings of the National Academy of Sciences of the United 




Nav channels are embedded in a multicomponent membrane signaling 
complex that plays a crucial role in cellular excitability. Although the mechanism 
remains unclear, β-subunits modify Nav channel function and cause debilitating 
disorders when mutated. While investigating whether β-subunits also influence 
ligand interactions, we found that β4 dramatically alters toxin binding to Nav1.2. 
To explore these observations further, we solved the crystal structure of the 
extracellular β4 domain and identified 58Cys as an exposed residue that, when 
mutated, eliminates the influence of β4 on toxin pharmacology. Moreover, our 
results suggest the presence of a docking site that is maintained by a cysteine 
bridge buried within the hydrophobic core of β4. Disrupting this bridge by 
introducing a β1 mutation implicated in epilepsy repositions the 58Cys-containing 
loop and disrupts β4 modulation of Nav1.2. Overall, the principles emerging from 
this work (i) help explain tissue-dependent variations in Nav channel 
pharmacology; (ii) enable the mechanistic interpretation of β-subunit–related 
disorders; and (iii) provide insights in designing molecules capable of correcting 
aberrant β-subunit behavior 
 
Contributions: The contents of figures 2-4, 2-5, 2-6, 2-10, and 2-11 and Table 





Nav channels play a key role in cellular communication by manipulating 
the transmembrane voltage gradient to encode and propagate vital information 
rapidly over long distances [24]. Consequently, mutations that modify Nav 
channel activity underlie debilitating neurological diseases, muscular disorders, 
and pain syndromes [72, 103]. Typically, Nav channels are part of a membrane-
embedded signaling complex that involves various integral membrane proteins 
[11]. The significance of this environment for proper channel function is 
highlighted by divergent Nav channel responses to changes in membrane 
voltage when expressed in native tissues or in heterologous systems. β-Subunits 
are prominent members of the Nav channel signaling complex but do not 
contribute to the ion-conducting pore [8]. Instead, they are multifunctional single-
transmembrane segment glycoproteins that (i) modulate the gating properties of 
voltage-gated ion channels; (ii) regulate Nav channel trafficking and expression 
levels; and (iii) promote cell adhesion and migration [8, 145, 147, 148, 152, 156, 
157, 206-208]. Of the four known β-subunits and their splice variants [138-142, 
209], β4 is unique in that it enables resurgent current, a feature that renders 
certain Nav channel isoforms capable of high-frequency firing in excitable tissues 
[179]. Moreover, aberrant behavior of the ubiquitously expressed β4 subunit has 
been implicated in long-QT syndrome (LQTS) [197], LQTS-associated Sudden 
Infant Death Syndrome [198], atrial fibrillation [196], Huntington’s disease [205], 
and prostate cancer [210], possibly through dysregulation of the Nav channel 
signaling complex. β4 also is targeted by β- and γ-secretase enzymes from the 
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amyloidogenic pathway, a recent observation that suggests a potential 
contribution of this particular subunit to the development of Alzheimer's disease 
[211]. 
Despite accumulating evidence supporting an important contribution to 
neuronal excitability and various health disorders [212], fundamental questions 
about the molecular mechanisms underlying β4 interaction with Nav channels 
remain unanswered. Moreover, the notion that the β4 subunit shapes the overall 
pharmacological sensitivities of the Nav channel signaling complex remains 
unexplored. However, altered ligand interactions may be exploited to detect the 
presence of β4 in normal or pathological conditions [213]. Here, we investigated 
whether β-subunits influence Nav channel sensitivity to molecules isolated from 
animal venom and discovered that β4 can drastically alter the response of the 
neuronal Nav1.2 isoform to spider and scorpion toxins that target paddle motifs 
within Nav channel voltage sensors. To elucidate the machinery underlying this 
observation, we solved the crystal structure of the extracellular β4 domain and 
found a 58Cys-containing binding interface that is involved in Nav channel 
modulation of toxin pharmacology by β4. Remarkably, dismantling the strictly 
conserved internal cysteine bridge in β4 by introducing a β1 mutation implicated 
in epilepsy [188] does not preclude protein folding and trafficking to the 
membrane. However, conformational changes induced by the mutation perturb 
the 58Cys-containing loop and disrupt β4 interaction with Nav1.2, in turn altering 






β-subunits shape Nav channel pharmacology.  
Although the influence of β-subunits on ion channel gating is well 
documented [8], little is known about their ability to manipulate the 
pharmacological sensitivities of Nav channel signaling complexes [172, 213, 
214]. To investigate the extent to which these versatile glycoproteins modify 
ligand interactions, we applied seven toxins from spider, scorpion, sea anemone, 
and wasp venom (ProTx-I, ProTx-II, TsVII, AaHII, LqqIV, ATX-II, and β-PMTX) as 
well as two drugs (lidocaine and ambroxol) to Xenopus oocytes expressing the 
neuronal Nav1.2 isoform and determined potential changes in ligand 
susceptibility induced by the presence of each of the four β-subunits. We 
uncovered multiple conditions in which Nav1.2’s sensitivity to a particular toxin 
was modified by β-subunits, whereas sensitivity to neither drug was significantly 
affected (Fig. 2-1, Fig. 2-2, and Table 2-1). For example, the sea anemone toxin 
ATX-II interacts exclusively with the Nav1.2 domain IV voltage sensor to inhibit 
fast inactivation, resulting in a large increase in inward sodium ion flow [215]. 
When β2 is present, 100 nM ATX-II still prevents Nav1.2 from inactivating rapidly; 
however, the peak sodium current increases only marginally (Fig 2-1). A similar 
effect is seen when 100 nM of the domain IV-targeting scorpion toxin LqqIV is 
applied to Nav1.2 coexpressed with β1 [binding site identification is given in Fig. 
2-3 [31]]. In this instance, however, LqqIV also shifts the steady-state inactivation 
curve to more positive potentials (V1/2 from −57 mV to −48 mV; P ≤ 0.001), 
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thereby increasing channel availability to open in response to membrane 
depolarizations (Fig. 2-1). In contrast, the related scorpion toxin AaHII [31] 
decreases Nav1.2 availability when coexpressed with β2 (V1/2 from −42 mV to 
−61 mV; P ≤ 0.001) or β4 (V1/2 from −45 mV to −63 mV; P ≤ 0.001). 
Interestingly, the most striking effects on toxin susceptibility are observed 
when Nav1.2 is expressed together with the β4 subunit. First, the tarantula toxin 
ProTx-II has been shown to interact with the voltage sensors in domains I, II, and 
IV of Nav1.2 and to inhibit channel opening [31, 216]. However, in the presence 
of β4, Nav1.2 is dramatically less inhibited, suggesting that β4 may prevent 
ProTx-II from interacting with one or more of its receptor sites (Fig. 2-2B). 
Second, the structurally unrelated scorpion toxin TsVII promotes Nav channel 
opening by preferentially interacting with the voltage sensor in domain II and 
stabilizing it in an activated state [31, 217]. Without β-subunits present, 500 nM 
TsVII causes Nav1.2 to open at more negative voltages, although the maximal 
conductance of the channel is not affected. In contrast, TsVII greatly decreases 
Nav1.2 maximal conductance with a smaller shift in activation voltage when β4 is 
present (Fig. 2-2C), raising the possibility that this β-subunit exerts an influence 
on the domain II voltage sensor. Next, we crystallized the extracellular β4 domain 







The β4 subunit structure reveals an exposed cysteine. 
Despite their impact on the functional and pharmacological properties of 
Nav channels, tertiary structural information about β-subunits has been lacking. 
To address this inadequacy, we solved the crystal structure of the extracellular 
β4 domain (residues 32–157) at 1.7 Å resolution (Fig. 2-4, Fig. 2-5, and Table 2-
2) and found that this subunit has a compact fold, similar to that of 
immunoglobulins, that consists of 10 β-strands and two 310 helices [187, 218]. A 
low sequence complexity suggests that the upstream region of this domain 
(residues 1–31) is likely to be disordered in the absence of a binding partner, 
because constructs containing this particular segment result in protein 
aggregation. Moreover, a large portion of this region also may serve as a 
membrane-targeting signal sequence that is proteolytically cleaved during 
cellular processing [142]. Overall, the structure is held together by a buried 
disulfide bridge connecting the β2–β3 loop with the β8-strand which is flanked by 
68Trp, a residue conserved among all β-subunit isoforms. On the other side, it 
packs against 114Ile and 133Val, both of which correspond to the similar Ile, Val, or 
Leu residues in other β-subunits (Fig. 2-4C). Because of the strictly conserved 
nature of the protein core (Fig. 2-4D). it is likely that the buried disulfide bond has 
a major effect on the stability of the protein. Another stabilizing element in the β4 
structure is an ion-pair network involving two hydrogen bonds between 98Asp and 
100Arg, which forms two additional bonds with 125Asp, as well as a hydrogen bond 
between 77Lys and 125Asp that is mediated by a water molecule (Fig. 2-4E). Such 
networks of ionic pairs are more stabilizing than individual salt bridges because 
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of lower desolvation penalties [219]. Next, we examined the surface of β4 for 
unique structural features that may contribute to an interaction with Nav1.2. 
The β4 extracellular domain consists of solvent-accessible surface area of 
∼6,600 Å2 with one side exposing multiple hydrophobic side chains as well as 
residue 58, a Cys in WT protein but replaced by Ala to facilitate crystallization 
(Fig. 2-6A). 58Cys is located in a loop between the β2- and β3-strands and is 
lined by two hydrophobic pockets, thereby placing it in an ideal position to form a 
disulfide bond with another free Cys (Fig. 2-4A). Nonetheless, conformational 
changes resulting from the C58A mutation are unlikely, because the residue is 
located at the protein surface, and the mutant has a thermal stability similar to 
that of WT β4 (Fig. 2-6B). Strikingly, the position of 58Cys in β4 corresponds to 
that of the Cys (26Cys) thought to be involved in linking β2 to Nav1.1 [144]. Here, 
removing the covalent bond with Nav1.1 by mutating 26Cys to Ala results in an 
altered subcellular localization pattern of β2. Given the prominent position of 
58Cys in the β4 crystal structure and the functional importance of the 
corresponding residue in β2, we asked whether 58Cys plays a role in determining 
the influence of β4 on Nav1.2 toxin pharmacology. 
 
Mutating 58Cys in β4 restores Nav1.2 sensitivity to ProTx-II.  
To examine whether the ability of β4 to alter Nav1.2 toxin susceptibility 
depends on a disulfide bond involving 58Cys, we initially incubated Nav1.2/β4-
expressing oocytes with a reducing agent (DTT) for 60 min. Subsequently, we 
transferred the oocyte to a physiological recording solution and tested whether 
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Nav1.2 regains sensitivity to ProTx-II (Fig. 2-7). Even though all exposed 
cysteines may have been reduced, channel-gating behavior is not affected 
significantly; however, we observe that the toxin now inhibits Nav1.2 as if no β4 
is present, suggesting that the disulfide bond between 58Cys and Nav1.2 is 
crucial in modifying channel susceptibility to ProTx-II in the presence of β4. 
Next, we replaced 58Cys in β4 with Ala and exploited the presence of an 
intracellular Myc-tag to determine whether cellular trafficking of this mutant is 
altered. By doing so, we discovered that the WT β4 protein and the C58A mutant 
are produced in large quantities (Fig. 2-8A). Moreover, biotinylation experiments 
reveal the presence of both variants within the lipid membrane, most likely in a 
glycosylated form [220]. When β4 glycosylation is removed using peptide-N-
glycosidase F (PNGase F), an amidase that releases N-linked oligosaccharides, 
the molecular weight of the protein on the membrane surface corresponds to the 
predicted mass of β4 (28 kDa) (Fig. 2-9) [142]. Having established the membrane 
insertion of β4 and the C58A mutant (without or in the presence of Nav1.2; Fig. 
2-9), we next applied 100 nM ProTx-II to cells expressing Nav1.2/β4 C58A and 
observed a level of inhibition similar to that obtained when no β4 is present (Fig. 
2-8 B and C). When comparing the affinities of ProTx-II for Nav1.2 in more detail, 
we note an approximately fivefold decrease in the presence of β4 compared with 
control conditions without β4 (IC50 from 32 ± 1 nM to 164 ± 33 nM with slopes of 
1.9 ± 0.1 and 1.6 ± 0.3, respectively). Moreover, the affinity of ProTx-II for Nav1.2 
coexpressed with the C58A mutant (IC50 = 33 ± 2 nM with a slope of 1.7 ± 0.1) is 
comparable to the IC50 obtained on cells lacking β4 (Fig. 2-8D). Taken together, 
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our results identify 58Cys as a reactive residue that, when mutated, eliminates the 
influence of β4 on Nav1.2 toxin pharmacology by perturbing a unique disulfide 
bond with the Nav channel. 
Mapping clinically relevant β-subunit mutations onto the β4 structure. 
Reflecting its medical importance, atypical β-subunit behavior has been 
implicated in various epilepsy syndromes and cardiac disorders [8]. However, 
little is known about the relationship between the structural and functional 
consequences of mutations and a particular clinical phenotype. Our results 
presented here provide a unique opportunity to map abnormalities within the 
extracellular domain onto a high-resolution β4 crystal structure and to explore 
their mode of action (Fig. 2-10 and Table 2-3). For example, R85H and E87Q in 
β1 have been associated with atrial fibrillation and Brugada syndrome, 
respectively [192, 193]. Both residues are located near or within the β5–β6 loop 
and form a patch of solvent-accessible surface area (Fig. 2-10A), suggesting that 
these amino acids are part of an important functional interface that may be 
targeted by therapeutics [212]. Similarly, the R125L variant has been identified in 
patients who have generalized epilepsy plus febrile seizures plus (GEFS+) [189], 
whereas R125C may contribute to the occurrence of Dravet syndrome [190]. 
Because this residue lines a pocket near the conserved 58Cys, the addition of a 
Cys may interfere with the formation of a proper disulfide bond with the Nav 
channel (Fig. 2-10A). 
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Surface-exposed mutations may hint at a disruption of a functional 
interface, whereas buried substitutions are likely to affect overall protein folding. 
For instance, in patients who suffer from Dravet syndrome [191] a Pro residue 
replaces a concealed Ile at position 106 in β1, where it is likely to interfere with 
protein folding (Fig. 2-10A). The V110I mutation in β3 has been linked to 
Brugada syndrome and also affects a residue buried within a hydrophobic core, 
resulting in reduced channel expression [202]. Interestingly, the first 
epileptogenic mutation attributed to Nav channel β-subunits is a Cys-to-Trp 
substitution that disrupts the disulfide bridge within the extracellular domain of β1 
[188]. Although the protein traffics to the membrane, the precise mechanism 
relating this C121W variant to the resulting GEFS+ disease phenotype is still a 
matter of debate [221-223]. We chose to mutate the corresponding residue in β4 
(C131W and C131A) to determine whether disrupting this strictly conserved 
internal disulfide bond repositions 58Cys to such an extent that it cannot interact 
with the Nav channel.  
Even though a lack of space for a Trp side chain at the 131Cys position 
suggests that this mutant should be unable to fold properly and aggregate, both 
the C131W and the C131A construct can be purified to obtain nonaggregated 
protein, as indicated by size-exclusion chromatography (Fig 2-11). Moreover, 
thermal stability measurements in the presence of reducing agent [14 mM 2-
mercaptoethanol (2-ME)] only show ∼4-°C and ∼7-°C decreases in melting 
temperatures for C131W and C131A, respectively, compared with WT (Fig. 2-
6B). The presence or absence of 2-ME did not affect the melting curves for the 
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two mutants, and we did not observe an interpretable melting curve for WT β4 
without reducing agent, an observation that is consistent with the major 
stabilizing effect of a disulfide bond. Taken together, these results demonstrate 
that, although the disulfide bond adds to stability, it is not strictly required for 
folding. 
To explore this surprising result further, we next solved the crystal 
structure of the C131W construct at a resolution of 1.7 Å and found that the 
mutation results in conformational changes at multiple positions (Fig. 2-10B). 
Because the location of 144His in the β9–β10 loop would clash with the bulky Trp 
residue, this residue has swung away completely, and the β9–β10 loop adopts a 
β-strand conformation that results in a merged β9–β10 strand. In addition, 53Cys 
no longer is constrained by the disulfide bond, resulting in a dramatic shift of the 
β2–β3 loop (∼5.2 Å) within the main chain. This shift of the β2–β3 loop in turn 
shifts the positions of the neighboring β4–β5 loop (∼6 Å) and the β6–β7 loop 
(∼6.8 Å), resulting in complete remodeling of the surface. Because the β2–β3 
loop contains the functionally important 58Cys residue, the C131W mutation 
remodels the Nav channel-binding interface, potentially altering the functional 
and pharmacological properties of the Nav channel signaling complex. To 
substantiate this notion, we tested whether the C131W mutant indeed loses its 





The C131W mutation alters the influence of β4 on Nav1.2 toxin 
pharmacology.  
To examine the effect of the C131W substitution on Nav1.2 toxin 
susceptibility, we first determined whether cellular trafficking of this mutant is 
altered. Similar to WT β4, C131W is produced in large amounts (Fig. 2-12A); 
however, a nonquantitative Western analysis of total cell lysate uncovers 
potential alterations in glycosylation patterns that may complicate protein 
separation from the endoplasmatic reticulum. Nonetheless, biotinylation 
experiments reveal the presence of C131W within the oocyte membrane (Fig. 2-
12A). Indeed, when glycosylation is removed using PNGase F, the molecular 
mass of the C131W mutant on the membrane surface closely matches the 
predicted mass of β4 [142]. These results are consistent with previously reported 
observations with the β1 C121W mutant in a mouse model for epilepsy [224] and 
in human embryonic kidney cells stably expressing Nav1.1 [156]. Subsequently, 
we applied 100 nM ProTx-II to cells expressing Nav1.2/β4 C131W and observed 
a level of inhibition over a wide voltage range similar to that obtained when 
neither β4 nor the C58A mutant is present (Fig. 2-12 B and C). Because the 
C131W mutant traffics to the membrane surface in oocytes, results from the 
ProTx-II experiment suggest that 58Cys no longer may be able to interact with 
Nav1.2. It is worth noting that our Western blot analysis (Fig. 2-12A) does not 
rule out the possibility that impaired C131W trafficking in oocytes may contribute, 
at least in part, to the restoration of Nav1.2 toxin sensitivity. Together with our 
crystallographic data, these functional results show that, although the conserved 
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cysteine bond is not strictly required to produce folded protein, it does dictate the 






β-Subunits are vital members of the larger Nav channel signaling complex 
in which they modify channel function to fine-tune the electrical excitability of 
native tissues [8, 145, 156-158]. The goal of the present study was to investigate 
the interaction of β-subunits with Nav channels on a molecular level and the role 
of these ancillary proteins in shaping the pharmacological sensitivities of the 
neuronal Nav1.2 isoform. Our experiments with an extensive collection of animal 
toxins establish that β-subunits can alter Nav1.2 pharmacology drastically and 
that the resulting effects vary among β-subunit–toxin pairs (Fig. 2-1, Fig. 2-2, and 
Table 2-1). For example, β4 coexpression results in an approximately fivefold 
decrease in the affinity of ProTx-II for Nav1.2, whereas the same subunit reduces 
sodium influx upon TsVII application, an effect that is not observed with the WT 
channel or in the presence of β1–3. It is worth considering potential principles 
underlying β-subunit modulation of Nav channel pharmacology. For example, a 
toxin may compete with a β-subunit for binding to a particular region within 
Nav1.2. For instance, LqqIV interacts with the domain IV voltage sensor (Fig. 2-
3), and its effect is influenced by β1, suggesting a direct or allosteric interaction 
of this particular subunit with domain IV within Nav1.2 [150, 151, 162]. 
Alternatively, ligands may bind directly to β-subunits [225], an intriguing concept 
that also has been observed with the voltage-gated calcium channel inhibitor 
gabapentin, which acts through the transmembrane α2δ subunit [226]. 
Interestingly, β3 is unable to modulate Nav1.2 susceptibility to any of the toxins 
we tested, but this particular subunit influences lidocaine binding to the neonatal 
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Nav1.3 and cardiac Nav1.5 isoform [227, 228]. This result highlights the unique 
character of the interaction between a particular β-subunit and a given Nav 
channel isoform [229]. 
Because the most striking effects on Nav1.2 toxin susceptibility are 
observed with the β4 subunit, we crystallized its extracellular domain and 
identified 58Cys as a surface-exposed residue that, when mutated, abolishes the 
impact of β4 on ProTx-II binding to Nav1.2 (Fig 2-4 and 2-6). Because this Cys is 
conserved in β2 and β4, it likely belongs to a universal docking site for multiple 
Nav1 channel isoforms. The two other conserved cysteines (53Cys and 131Cys) 
are buried within a hydrophobic core where they form a disulfide bond. When 
131Cys is mutated to Trp or Ala (Fig. 2-6B), we surprisingly find that the 
extracellular domain is still folded, thus demonstrating that the cysteine bridge is 
not strictly required for protein folding. However, the crystal structure of the 
C131W mutant, which mimics a well-established epileptogenic mutation found in 
β1, reveals conformational changes at multiple locations, including the loop that 
contains the conserved 58Cys (Fig. 2-10B). Subsequently, an important role of 
the buried cysteine bridge may be to maintain a specific local structure that 
allows an interaction with the Nav channel and that, when disrupted (Fig 2-12), 
creates a loss-of-function phenotype that relates to disorders such as GEFS+ 
[188]. 
Collectively, the functional and crystallographic results reported here shed 
light on the intricate interactions of β4 within the Nav channel signaling complex 
and establish a key role for β-subunits in shaping Nav1.2 pharmacology. As 
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such, an important concept emerging from our work is that β-subunits provide 





Materials and Methods 
 
Toxin Acquisition and Purification. 
ProTx-I and ProTx-II [230] were acquired from Peptides International, β-
PMTX [231] was obtained from Alomone Laboratories, and ATX-II [232], 
lidocaine, and ambroxol were from Sigma-Aldrich. AaHII from Androctonus 
australis hector venom, TsVII from Tityus serrulatus venom, and LqqIV from 
Leiurus quinquestriatus were purified as described previously [233-235]. Toxins 
were kept at −20 °C, and aliquots were dissolved in appropriate solutions 
containing 0.1% BSA. 
Two-Electrode Voltage-Clamp Recording from Xenopus Oocytes.  
The DNA sequences of rNav1.2a [236], rβ1–4 (acquired from Origene and 
modified for oocyte expression), and of the C58A and C131W mutants were 
confirmed by automated DNA sequencing, and cRNA was synthesized using T7 
polymerase (mMessage mMachine kit; Ambion) after linearizing the DNA with 
appropriate restriction enzymes. LqqIV binding site experiments on chimeric 
voltage-gated potassium channels were carried out as previously described [31]. 
Channels were expressed together with a β-subunit (1:5 molar ratio) in Xenopus 
oocytes that were incubated at 17 °C in 96 mM NaCl, 2 mM KCl, 5 mM Hepes, 1 
mM MgCl2, 1.8 mM CaCl2, and 50 g/mL gentamycin (pH 7.6) with NaOH for 1–2 
d after cRNA injection, and then were studied using two-electrode voltage-clamp 
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recording techniques (OC-725C; Warner Instruments) with a 150-μL recording 
chamber. Data were filtered at 4 kHz and digitized at 20 kHz using pClamp 10 
software (Molecular Devices). Microelectrode resistances were 0.5–1 MΩ when 
filled with 3 M KCl. The external recording solution (ND100) contained 100 mM 
NaCl, 5 mM Hepes, 1 mM MgCl2, and 1.8 mM CaCl2 (pH 7.6) with NaOH. All 
experiments were performed at room temperature (∼22 °C). Leak and 
background conductances, identified by blocking the channel with tetrodotoxin 
(Alomone Laboratories), have been subtracted for all Nav channel currents. All 
chemicals used were obtained from Sigma-Aldrich unless otherwise indicated. 
Analysis of Channel Activity and Toxin–Channel Interactions. 
Voltage–activation relationships were obtained by measuring steady-state 
currents and calculating conductance (G). In representative cases a Boltzmann 
function was fitted to the data according to:  
where G/Gmax is the normalized conductance, z is the equivalent charge, V1/2 is 
the half-activation voltage, F is Faraday's constant, R is the gas constant, and T 
is temperature in Kelvin. Occupancy of closed or resting channels by ProTx-II 
and other toxins was examined using negative holding voltages when open 
probability was very low, and the fraction of uninhibited channels (Fu) was 
estimated using depolarizations that are too weak to open toxin-bound channels, 
as described previously [31]. After the toxin was added to the recording chamber, 
the equilibration between the toxin and the channel was monitored using weak 
depolarizations elicited at 5-s intervals. Concentration dependence for ProTx-II 
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inhibition of Nav channels is plotted as Fu measured at negative voltages versus 
toxin concentration. A Hill equation was fitted the data to obtain affinity values. 
Off-line data analysis was performed using Clampfit 10 (Molecular Devices) and 
Origin 8 (OriginLab). 
Nonquantitative Biochemical Assessment of β4 Production in Xenopus 
Oocytes.  
Batches of 20 oocytes expressing Nav1.2, Nav1.2/β4, Nav1.2/β4 C58A, 
and Nav1.2/β4 C131W were washed with ND100 and incubated with 0.5 mg/mL 
Sulfo-NHS-LC-biotin (Pierce) for 30 min. Oocytes were thoroughly washed again 
(by pipetting up and down) in ND100 before lysis in 400 μL buffer H (1% Triton X-
100, 100 mM NaCl, 20 mM Tris⋅HCl, pH 7.4) plus protease inhibitors (Clontech). 
All subsequent steps were performed at 4 °C. Lysates were shaken gently for 15 
min and then were centrifuged at 16,200 × g for 3 min. The pellet was discarded, 
and the supernatant was transferred to a fresh 1.5-mL Eppendorf tube; 40 μL of 
supernatant was stored at −80 °C for later use as the whole-cell protein aliquot. 
Then 200 μL of hydrophilic streptavidin magnetic beads (New England Biolabs) 
was added, and the sample was shaken gently at 4 °C overnight. Beads were 
washed six times with buffer H and were resuspended in 40 μL buffer H, after 
which biotinylated protein was dissociated from the beads by the addition of 40 
uL 1× LDS loading buffer plus reducing agent [final concentration: 10% (vol/vol) 
2-ME, 50 mM DTT] and boiling at 95 °C for 5 min. Deglycosylated samples were 
prepared by incubating the surface protein aliquot with PNGase-F and 1% 
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Nonidet P-40 at 37 °C for I h. All samples were diluted appropriately in buffer H to 
give roughly equal protein concentrations, as measured by absorbance at 280 
nM. Then 7.5 μL of the supernatant was run on a 10% (wt/vol) Bis-Tris NuPAGE 
Novex Mini-Gel (Invitrogen) with 3-(N-morpholino)propanesulfonic acid running 
buffer and were analyzed by Western blot analysis. Nitrocellulose membranes 
were probed with 1:1,000 mouse anti-Myc antibody (Cell Signaling Technologies) 
as the primary antibody and 1:10,000 goat anti-mouse HRP-conjugated antibody 
(Thermo-Fisher Scientific) as the secondary antibody. Membranes were 
incubated for 5 min with an enhanced chemiluminescent substrate [237] before 
imaging. 
Production of the β4 Extracellular Domain. 
Human β4 (hβ4) (32-157) acquired from OriGene was cloned into 
pET28HMT [238]. Mutations were introduced using the QuikChange kit from 
Stratagene according to the manufacturer’s instructions. Proteins were 
expressed at 18 °C in Escherichia coli Rosetta (DE3) pLacI strains (Novagen), 
were induced at an OD600 of ∼0.6 with 0.3 mM isopropyl β-D-1-
thiogalactopyranoside, and were grown overnight before harvesting. Cells were 
lysed via sonication in buffer A (250 mM KCl and 10 mM Hepes, pH 7.4) 
supplemented with 25 µg/mL DNaseI and 25 µg/mL lysozyme. After 
centrifugation, the supernatant was applied to a PorosMC column (Tosoh 
Biosep), washed with buffer A plus 10 mM imidazole, and eluted with buffer B 
(250 mM KCl plus 500 mM imidazole, pH 7.4). The protein was dialyzed 
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overnight against buffer A and cleaved simultaneously with recombinant TEV 
protease. Next, the samples were run on another PorosMC column in buffer A, 
and the flowthrough was collected and dialyzed against buffer C (50 mM KCl plus 
20 mM Tris⋅Cl, pH 8.0), applied to a HiloadQ column (GE Healthcare), and eluted 
with a gradient from 0–30% buffer D (2 M KCl plus 20 mM Tris⋅Cl, pH 8.0). 
Finally, the samples were run on a Superdex200 gel-filtration column (GE 
Healthcare) in buffer A. The protein samples were exchanged with 25 mM KCl 
plus 10 mM Hepes (pH 7.4), concentrated to 10–20 mg/mL using Amicon 
concentrators (3 K molecular weight cut off; Millipore), and stored at −80 °C. 
Crystallization, Data Collection, and Structure Solution. 
Crystals were grown using the sitting-drop method at 4 °C. β4 (32-157) 
C58A was crystallized in 0.1 M Hepes (pH 7) and 15% (wt/vol) PEG 20000. The 
C131W mutant was crystallized in 0.2 M ammonium formate, 20% (wt/vol) PEG 
formate, and 20% (wt/vol) PEG 3350 at 4 °C. Crystals were flash-frozen after 
transfer to the same solution supplemented with 30% (vol/vol) glycerol. 
Diffraction experiments were performed at the Advanced Photon Source 
(Chicago) beamline 23-ID-D-GM/CA, and datasets were processed using XDS 
[239]. A search model was created by using only β-strands from Protein Data 
Bank (PDB) ID code 1NEU and with all side chains truncated to Ala. Molecular 
replacement was performed using Phaser [240], yielding poor initial phases 
which were improved via autobuilding in ARP/wARP [241]. The model was 
completed by successive rounds of manual model building in COOT [242] and 
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refinement using Refmac5.5 [243]. A simulated annealing composite omit map 
was calculated with CNS [244] to verify the absence of residual model bias. No 
residues were found to be in disallowed regions of the Ramachandran plot. All 
structure figures were prepared using PYMOL (DeLano Scientific). Coordinates 
are available in the PDB database (ID codes 4MZ2 and 4MZ3). 
Thermal Melting Experiments. 
The protein melting curves were measured by means of ThermoFluor 
experiments [238, 245]. Samples for melting curves contained 50 μL of 0.1 
mg/mL protein and 1× SYPRO Orange solution (Invitrogen) using the 
manufacturer’s instructions. The curves were measured in a DNA engine Opticon 
2 real-time PCR machine (Bio-Rad), using the SYBR green filter option. The 
temperature was ramped from 25–95 °C in 0.5-°C steps, with 15 s at each step. 
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Figure 2-1: Influence of β-subunits on the ligand susceptibility of the 
voltage-gated sodium channel Nav1.2. Effect of 100 nM ProTx-I (A), 100 nM 
ProTx-II (B), 500 nM TsVII (C), 100 nM AaHII (D), 500 nM ATX-II (E), 100 nM 
LqqIV (F), 10 μM β-PMTX (G), 10 mM lidocaine (LIDO) (H), and 500 μM 
ambroxol (AMBX) (I) (all saturating concentrations) on Nav1.2 without and in the 
presence of β-subunits. Normalized conductance–voltage relationships (G/Gmax; 
black filled circle/red filled circle) and steady-state inactivation relationships 
(I/Imax; black open circle/red open circle) are shown before (black) and after 
(red) toxin or drug application. Channel-expressing oocytes were depolarized in 






Figure 2-2: Influence of β4 on the ligand susceptibility of Nav1.2. (A–E) 
Effect of saturating concentrations [100 nM ProTx-I (A), 100 nM ProTx-II (B), 500 
nM TsVII (C), 100 nM LqqIV (D), and 500 μM ambroxol (AMBX) (E)] [31, 246] on 
Nav1.2 and Nav1.2/β4. (Left) Representative sodium currents are elicited by a 
depolarization to −20 mV before (black) and after (red) addition of toxin or drug 
from a holding potential of −90 mV. The x-axis is 10 ms; the y-axis is ∼0.5 μA. 
(Right) Normalized conductance–voltage relationships (G/Gmax; black filled 
circles) and steady-state inactivation relationships (I/Imax; black open circles) of 
the WT Nav1.2 channel with or without β4 coexpression are compared before 
(black circles) and after (red circles) toxin or drug application. β4 alters Nav1.2 
susceptibility to ProTx-II and TsVII, whereas ProTx-I, LqqIV, and AMBX are not 
affected. Channel-expressing oocytes were depolarized in 5-mV steps from a 
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holding potential of −90 mV. Boltzmann fit values are reported in Table 2-1. n = 




Figure 2-3: Sensitivity of Nav1.2 paddle chimaeras to LqqIV. (A) Effects of 
100 nM LqqIV on voltage-gated potassium channel 2.1 (Kv2.1) and chimaeras in 
which paddle motifs from each of the four domains (DI–IV) were transferred from 
Nav1.2 into Kv2.1 (1). Normalized tail current–voltage activation relationships are 
shown, with tail current amplitude plotted against test voltage before (black filled 
circles) and in the presence of (other colors) toxin. Data reveal that LqqIV 
selectively targets the paddle motif in DIV of Nav1.2. The holding voltage was 
−90 mV, test pulse duration was 300 ms, and the tail voltage was −60 mV (−80 
mV for DIII). (B) Potassium currents elicited by depolarizations near the foot of 
the voltage–activation curve for Kv2.1 and chimaeras in the absence and 








Figure 2-4: Crystal structure of the β4 extracellular domain. (A and B) Two 
views of the hβ4 extracellular domain, rotated by 180° around a vertical axis. β-
Strands are in blue; 310 helices are in red. Dotted lines indicate a flexible region 
that is invisible in the electron-density map. The conserved cysteine bridge is 
shown in stick format, with the sulfur atoms colored yellow. The C58A mutation is 
indicated as A58, and three potential glycosylation sites are shown in as 45Asn 
(N45), 71Asn (N71), and 113Asn (N113). “To TM” indicates the position at which 
the single-transmembrane helix starts; N and C specify the N- and C-terminal 
ends of the structured part of the extracellular domain, respectively. (C) 
Sequence alignment of the extracellular regions of hβ1–4 with the secondary 
structure of β4 shown above. Amino acids conserved between β4 and other β-
subunits are in bold, and known β-subunit–related disease mutations are in red. 
Conserved cysteines are highlighted by a gray background and the C58A locus 
by a green background. (D) Close-up view of the disulfide bond showing the 
nearby conserved hydrophobic core. (E) Close-up view of the ion-pair network 
formed by hydrogen bonds between 98Asp and 100Arg, which forms two additional 







Figure 2-5: Omit map of the β4 core. A stereo view of a simulated annealing 
composite omit map of the β4 subunit core contoured at 1σ. The 53C–131C 





Figure 2-6: Surface representation and thermal stability of the β4 
extracellular domain. (A) Surface representation of the β4 extracellular domain. 
Hydrophobic side chains are indicated in green, carboxyl groups of Asp and Glu 
are shown in red, and the positively charged nitrogen groups of Lys and Arg are 
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in blue. The position of 58Cys is shown in yellow; other select residues are 
labeled for reference purposes. (B) ThermoFluor experiments showing average 
melting curves for WT β4 and three mutants under reducing conditions (14 mM 
2-ME). The melting temperatures are WT: 42.2 ± 0.1 °C; C58A: 42.2 ± 0.2 °C; 
C131W: 38.3 ± 1.1 °C; and C131A: 35.1 ± 0.4 °C (SDs are the results of three 
measurements). The melting curves for C131W and C131A are identical in the 





Figure 2-7: Reducing 58Cys abolishes the effect of β4 on ProTx-II binding. 
(A) Normalized conductance–voltage relationships (G/Gmax) of Nav1.2 and 
Nav1.2/β4- expressing oocytes are shown before (black circles) and after (red 
circles) the application of 100 nM ProTx-II in control (no incubation; panels 1 and 
3) and after 60 min incubation with 200 μM DTT and 100 μM EDTA (panels 2 
and 4). As shown in this figure, Nav1.2 opening is not significantly affected by the 
treatment; however, Cys reduction results in an increased affinity of ProTx-II for 
the Nav channel in the presence of β4. Channel-expressing oocytes were 
depolarized in 5- mV steps from a holding potential of −90 mV. n = 3–5; error 
bars represent S.E.M. (B) Representative sodium currents are elicited by a 
depolarization to −20 mV before (black) and after (red) the addition of 100 nM 






Figure 2-8: Influence of β4 C58A on ProTx-II susceptibility of Nav1.2. (A) 
Correct cellular trafficking of WT β4 and the C58A mutant in oocytes is shown 
using Western blot analyses by probing for an intracellular β4 Myc-tag combined 
with primary amine biotinylation of surface proteins. The gel demonstrates that 
the oocytes produce WT β4 as well as the C58A mutant and that the membrane-
inserted protein is heavily glycosylated. The open arrow indicates glycosylated 
β4. A more detailed gel showing deglycosylated β4 is shown in Fig. 2-9. (B) The 
effect of 100 nM ProTx-II on Nav1.2, Nav1.2/β4, and Nav1.2/β4 C58A. 
Representative sodium currents are elicited by a depolarization to −20 mV before 
(black trace) and after (red trace) the addition of ProTx-II from a holding potential 
of −90 mV. The x-axis is 10 ms; the y-axis is ∼0.5 μA. (C) Normalized 
conductance–voltage relationship (G/Gmax) of the Nav1.2/β4 C58A channel 
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without (black filled circles) and in the presence (red filled circles) of ProTx-II. (D) 
Affinity (IC50) of ProTx-II interacting with WT Nav1.2 (black filled circles), 
Nav1.2/β4 (red filled circles), and Nav1.2/β4 C58A (black open circles connected 
by the dashed line). The concentration dependence for toxin inhibition is plotted 
as the fraction of uninhibited channels (Fu). Lines represent a fit with the Hill 
equation, and IC50 values are mentioned in the text. n = 3–5 for each toxin 





Figure 2-9: β4 and the C58A mutant are glycosylated and traffic to the 
membrane. (A) Western blot analysis and biotinylation experiments demonstrate 
the presence of β4 and the C58A mutant on the oocyte membrane surface, albeit 
in a glycosylated form (open arrowhead). Removing β4 glycosylation using 
Peptide-N-Glycosidase F (PNGase F) incubation reveals the correct predicted 
molecular mass of 28 kDa (filled arrowhead).This figure shows data related to 
that shown in Fig. 4 but over a more extensive range of protein masses. (B) 
Without Nav1.2, β4 (1) and the C58A mutant still traffic to the oocyte membrane 





Figure 2-10: Disease-related mutations mapped onto the β4 extracellular 
domain structure and crystal structure of the β4 C131W variant. (A) Arrows 
indicate the positions of known β1 and β3 disease mutations (summarized 
in Table 2-3) mapped onto the β4 extracellular domain. The corresponding 
residue substitutions are shown in parentheses, and the positions of 53Cys 
and 58Cys are indicated by a yellow stick for reference purposes. Two mutations 
occur within inserted regions, and the main chains of amino acids next to these 
insertions are also colored black. (B) The crystal structure of the C131W mutant 
(white) superimposed onto the WT β4 crystal structure (blue). Shifts in the 
positions of several regions are indicated by double-headed arrows, and select 
side chains are shown for reference purposes. 58Cys in the C131W structure 
appears to have a 2-ME molecule attached to it, further highlighting its reactivity. 




Figure 2-11: Gel-filtration chromatograms of β4, C131W, and C131A. All 
three chromatograms display a predominant peak corresponding to monomeric 





Figure 2-12: Influence of β4 C131W on ProTx-II susceptibility of Nav1.2. (A) 
Cellular trafficking of WT β4 and the C131W mutant in oocytes is shown using 
nonquantitative Western blot analyses by probing for an intracellular Myc-tag 
combined with primary amine biotinylation of surface proteins. The gel 
demonstrates that WT β4, as well as the C131W mutant, is produced and that 
the membrane-inserted protein is glycosylated. The open arrowhead indicates 
glycosylated protein, whereas the closed arrowhead represents deglycosylated 
protein. (B) Effect of 100 nM ProTx-II on Nav1.2/β4 C131W. Representative 
sodium current is elicited by a depolarization to −20 mV before (black trace) and 
after (red trace) the addition of ProTx-II from a holding potential of −90 mV. 
The x-axis is 10 ms; the y-axis is ∼0.5 μA. (C) Normalized conductance–voltage 
relationship (G/Gmax) of the Nav1.2/β4 C131W channel without (black filled 
circles) and in the presence of (red filled circles) 100 nM ProTx-II. n = 3–5; error 





Table 2-1: Influence of ligands on the gating properties of Nav1.2 and 
Nav1.2/βx. Results are the average of three to five oocyte recordings and errors 
are SEM. The table presents data related to Fig. 1 in the main text. *A statistically 
significant difference before and after toxin addition to Nav1.2 without or in the 




Nav1.2 Nav1.2/1 Nav1.2/2 Nav1.2/3 Nav1.2/4 



























































































































































































































































Data collection   
Space group  P 3     P32 2 1 P 1 21 1 
Cell dimensions     
    a, b, c (Å) 43.44,  43.44, 
108.38 
31.50,  42.50, 
89.20 
    a, b, g  ()  90.0,  90.0, 120.0 90.0, 91.5, 90.0 








Rsym or Rmerge 6.0 (70.1) 6.2 (53.8) 
I / sI 21.4 (2.9) 13.6 (2.6) 
Completeness (%) 99.9 (98.5) 98.8 (91.4) 
Redundancy 10.4 (8.9) 
 
3.6 (3.1) 
Refinement   
Resolution (Å) 27.0 –1.72 29.0-1.74 
No. reflections 13,205 22,945 
Rwork / Rfree 17.7/ 21.8 17.0/22.9 
No. atoms   
    Protein 907 1967 
    Water 126 280 
B-factors   
    Protein 30.4 24.7 
    Water 46.7 38.7 
R.m.s. deviations   
    Bond lengths (Å) 0.021 0.018 
    Bond angles () 1.925 1.894 
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Table 2-2: Data collection and refinement statistics. *For each structure, one 
crystal was used for data collection and structure determination. †Values in 







Disease phenotype β4 
residue 
Location  Solvent accesible 
surface area (Å2)** 
NaVβ1 R85H[247] Atrial fibrillation K96 End of β5 61.9  
 E87Q[248] Cardiac conduction 
defect 
D98 β5- β6 loop 21.4 





GEFS+ C131 β8. Affects conserved 
cystine bond. Buried. 
0.9 
 R125L[251] GEFS+ N135 End of β8. Lines pocket 
next to Cys58. 
14.3 
 R125C[252] Dravet syndrome N135 End of β8. Lines pocket 
next to Cys58. 
14.3 
 V138I[253] Idiopathic epilepsy / Insertion in β9-β10 loop / 
      
NaVβ3 V54G[254] Idiopathic ventricular 
fibrillation 
/ Insertion in β2-β3 loop / 
 Q89L[255] Colorectal cancer* D98 β5-β6 loop; surface 
accessible. 
21.4 










ARCHITECTURE OF THE BETA2/BETA4-NAV CHANNEL  
SIGNALING COMPLEX 
Chapter 3: Binary architecture of the Nav1.2-β2 signaling complex 
 
 
This chapter adapted from: 








To investigate the mechanisms by which β-subunits influence Nav channel 
function, we solved the crystal structure of the β2 extracellular domain at 1.35 Å. 
We combined these data with known bacterial Nav channel structural insights 
and novel functional studies to determine the interactions of specific residues in 
β2 with Nav1.2. We identified a flexible loop formed by 72Cys and 75Cys, a unique 
feature among the four β-subunit isoforms. Moreover, we found that 55Cys helps 
to determine the influence of β2 on Nav1.2 toxin susceptibility. Further 
mutagenesis combined with the use of spider toxins reveals that 55Cys forms a 
disulfide bond with 910Cys in the Nav1.2 domain II pore loop, thereby suggesting 
a 1:1 stoichiometry. Our results also provide clues as to which disulfide bonds 
are formed between adjacent Nav1.2 912/918Cys residues. The concepts emerging 
from this work will help to form a model reflecting the β-subunit location in a Nav 
channel complex. 
 
Contributions: The contents of figures 3-1, 3-2, 3-3, and 3-6 and Table 3-1 were 





Nav channels are part of membrane-embedded signaling complexes that 
initiate the rising phase of action potentials, a crucial event in generating and 
propagating electrical signals throughout the human body [1, 12]. As key 
components of these protein assemblies, β-subunits (1) modify Nav channel-
gating properties; (2) regulate channel trafficking and localization to distinct 
surface compartments; and (3) influence channel oligomerization [9, 257]. 
Moreover, β-subunits can alter the toxin pharmacology of Nav channels [78], a 
concept that has been exploited to detect their presence in heterologous 
expression systems or native tissues [213, 258-260]. Structurally, β-subunits are 
single-transmembrane segment glycoproteins with a short cytoplasmic C-
terminal tail and a large V-type immunoglobulin (Ig) extracellular domain that may 
participate in homophilic and heterophilic interactions, cell adhesion, and cell 
migration [9, 257, 261]. Although all β-subunits belong to the Ig family, recent 
atomic resolution information for the β3 and β4 extracellular domain revealed 
substantial differences in their 3D structure [146, 260]. Given their distinct 
features and functional roles, it has now become clear that each β-subunit 
structure should be obtained and assessed separately. Of the four known β-
subunits and their splice variants (β1–4; gene names Scn1b-Scn4b) [138-142], 
β2 and β4 form a disulfide bond with an unidentified Cys within particular Nav 
channel isoforms. In contrast, non-covalent interactions underlie β1 and β3 
association with Nav channels as well as other members of the voltage-gated ion 
channel family [9, 147-149, 257]. Aberrant behavior of the ubiquitously expressed 
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β2 and β4 subunits has been linked to disorders such as long-QT syndrome, 
atrial fibrillation, sudden infant death syndrome, and epilepsy, possibly through 
dysregulation of the Nav channel signaling complex [196-200]. Moreover, β2 has 
been implicated in neurodegenerative disorders and neuropathic pain and is 
therefore of potential interest for developing novel therapeutic strategies [169, 
262]. Finally, β2 is targeted by secretase enzymes, an observation that suggest a 
potential contribution to Alzheimer's disease [194, 195]. 
Despite accruing evidence supporting their clinical relevance, fundamental 
questions on the causal relationship between β2 mutations and disorders remain 
unanswered. In contrast, auxiliary proteins are the topic of herculean research 
efforts in other fields where their role as vital contributors to cellular function or in 
forming drug receptor sites is well established [226, 263-265]. To begin to 
appreciate β2 function and lay the foundations for constructing an interacting 
model with Nav channels, we first need to define the mechanism by which β2 
regulates Nav channel function. In particular, knowledge of the relative 
orientation of both partners will help to assess whether a mutation modifies 
channel function or influences complex assembly. To this end, we solved the 
crystal structure of the extracellular β2 domain at 1.35 Å and found a 55Cys-
containing binding region that modulates Nav1.2 toxin susceptibility by β2. Next, 
we exploited a combination of Nav channel mutagenesis, biochemistry, and β2-
induced alterations in spider toxin pharmacology to uncover a disulfide bond 
between 55Cys and a partnering Cys located in the domain II S5-S6 pore loop of 
Nav1.2. Remarkably, Nav1.5 and close relatives Nav1.8/Nav1.9 do not possess 
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a corresponding Cys, which may explain a lack of β2 effect on Nav1.5 toxin 
pharmacology. In concert with the available structural information on bacterial 
Nav channels [16, 17, 45, 46] our results provide conceptual insights into the 





Crystal structure of the human β2 extracellular region 
To begin to understand the functional relationship between human (h)β2 
and hNav channels at an atomic level, we solved the crystal structure of the 
extracellular hβ2 domain at a resolution of 1.35 Å (Fig. 3-1, Table 3-1). The 
construct encompasses residues 30–153 (Fig. 3-2), and contains a single Cys 
mutation (C55A) to facilitate crystallization [The C55A mutation is located on the 
protein surface and therefore unlikely to affect the overall structure (Fig. 3-1A and 
D).]. The hβ2 configuration displays an Ig-like fold, consisting of eleven β-strands 
and three 310 helices. Other than the mutated Cys (C55A), this domain contains 
four additional cysteines that are arranged in two bonds. The first, intra-subunit 
bond, is strictly conserved among all four β-subunit isoforms and is mediated by 
50Cys and 127Cys buried within the core where it links two opposing faces of the 
protein. The second intra-subunit bond is located within a loop that spans 
residues 70–77 and connects strand β5 to β6 via 72Cys - 75Cys (Fig. 3-1A and B). 
This loop constitutes a unique feature of hβ2 since corresponding cysteines are 
absent in β1, β3, and β4. Remarkably, this region displays a dual conformation in 
the crystal structure which indicates a high degree of flexibility (Fig. 3-1B). 
Although the overall hβ2 extracellular domain exhibits a similar fold 
compared to that of the previously reported hβ3 [146] and hβ4 [260] structures, 
considerable differences are observed. Aside from the distinct 72Cys - 75Cys 
disulfide bond, there are extensive variances in loop lengths and β strands, 
indicating that hβ2 and hβ4 have diverged substantially (Fig. 3-2A and C). Yet, at 
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a protein sequence level, hβ2 is most closely related to hβ4 (26% identical; 48% 
conserved) (Fig. 3-2D and E). Of note is that the N-terminal region of hβ2 is 
structured rather than disordered in hβ4, adding an additional short β strand (β1) 
which interacts with the novel β4 strand. The strand following the unique disulfide 
bond is shortened in hβ2 and two additional 310 helices can be seen, whereas 
one that is present in hβ4, no longer exists in hβ2. A comparison with the hβ3 
structure also shows substantial divergence in loop lengths at particular locations 
(Fig. 3-2B and C). The hβ3 extracellular domain misses the additional N-terminal 
β-strand; instead, its N-terminus is anchored via a disulfide bridge between 26Cys 
and 48Cys, resulting in positional shifts in excess of 15 Å. 
We previously found that 58Cys on the surface of β4 is crucial in 
modulating Nav1.2 susceptibility to toxins from spider and scorpion venom [260]. 
The hβ2 subunit possesses a corresponding Cys at position 55 that is located in 
a longer loop which may result in an altered spatial position of this residue when 
compared to hβ4 (Fig. 3-2A and C, Fig. 3-1D and E). In addition, the residues 
immediately N-terminal to 55Cys are stabilized through a β-strand interaction 
between strands β1 and β4, both of which are absent in hβ4. Taken together, 
these observations suggest that the environment of this key Cys may differ in 
both isoforms. To further examine the coupling of hβ2 to hNav1.2, we next 






Mutating 55Cys in hβ2 restores hNav1.2 toxin susceptibility 
Previously, we and others discovered that β-subunits can manipulate the 
pharmacological sensitivities of Nav channels [213, 260, 266]. In particular, β4 is 
capable of dramatically altering animal toxin binding to rat (r)Nav1.2a [260]. For 
example, the spider toxin ProTx-II [230] binds to voltage-sensing domains 
(VSDs) I, II, and IV in rNav1.2a [31], and is ∼five-fold less potent when β4 is 
present. [An intriguing concept is that ProTx-II may also bind directly to β4 [226]; 
however, our isothermal calorimetry experiments do not support this notion (Fig. 
3-3).] To examine whether this protective ability extends to hβ2, we expressed 
hNav1.2 in Xenopus oocytes and measured ProTx-II susceptibility without or in 
the presence of the β-subunit (Fig. 3-4, Table 3-2). Similar to β4, we observe that 
the hβ2 subunit expresses abundantly and traffics to the membrane (Fig. 3-5D) 
where it is able to reduce the degree of hNav1.2 current inhibition by ProTx-II. 
Specifically, 100 nM ProTx-II reduces hNav1.2 conductance to ∼17% of peak 
whereas the current remaining in the presence of hβ2 is typically more than 
∼64% of peak conductance, thereby demonstrating a protective effect. Other 
gating parameters such as conductance-voltage (G–V) and channel availability 
relationships are unaffected (Table 3-2). Next, we sought to determine if 55Cys in 
hβ2 is involved in reducing hNav1.2 susceptibility to ProTx-II by mutating this 
residue to an Ala. Indeed, the C55A mutant traffics to the membrane and causes 
ProTx-II inhibition of hNav1.2 to resemble that of the wild-type (WT) channel 
without hβ2 present (Fig. 3-4, Fig. 3-5B and C). Although Ala wields a small side 
chain and is often employed in mutagenesis studies, we also replaced 55Cys with 
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a Ser, as it most closely resembles Cys in terms of size and electric properties. 
Similar to WT hβ2 and C55A, the C55S mutation impaired neither channel 
expression nor surface trafficking (Fig. 3-5, Fig. 3-5C). Moreover, the extent of 
ProTx-II-induced hNav1.2 inhibition in the presence of C55S is indistinguishable 
from that of the channel alone (Fig. 3-5C, Table 3-2). Altogether, these results 
support the notion that hβ2 conveys ProTx-II protection to hNav1.2 via 55Cys and 
may relate to previous work in which the loss of the covalent link between rβ2 
and hNav1.1 disrupts the targeting of rβ2 to nodes of Ranvier and to the axon 
initial segment in hippocampal neurons [144]. 
In addition to 55Cys, the hβ2 crystal structure reveals a unique motif 
bearing a protruding disulfide-stabilized loop formed by 72Cys and 75Cys (Fig. 3-
1A and B). Remarkably, this additional loop is highly conserved in almost all 
species that express β2, suggesting an evolutionary conserved contribution to 
function (see Fig. 3-2, Fig. 3-6). To determine if this loop regulates the gating or 
pharmacological influence of hβ2 on hNav1.2, we mutated 72Cys and 75Cys to 
Ala (C72A C75A) but found that it is functionally indistinguishable from WT hβ2 
(Fig. 3-4, Fig. 3-5C). The C72A C75A mutant localizes to the oocyte membrane 
surface without or with hNav1.2 co-expression. Moreover, typical gating 
parameters and hNav1.2 inhibition by 100 nM ProTx-II in the presence of C72A 
C75A is similar to that observed for the channel when co-expressed with WT hβ2 
(Table 3-2). The lack of effect of the C72A C75A mutant on hNav1.2 function 
suggests that this disulfide bond is not essential for folding, and that its disruption 
may not significantly affect the position or environment of 55Cys. To verify this 
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hypothesis, we produced recombinant hβ2 extracellular domain containing three 
Cys mutations: C55A, C72A, and C75A. Size exclusion chromatography 
demonstrates that the mutant produces monomeric protein, indicating that the 
bond between 72Cys and 75Cys is unessential for folding (Fig. 3-1F). Furthermore, 
we obtained a crystal structure of the triple mutant at 1.85 Å which overlays well 
onto the C55A structure (Fig. 3-1C). The only significant difference is situated in 
the loop containing both cysteines, which now displays a single conformation. 
Although the spatial organization of this loop does not seem to impact the ability 
of hβ2 to modulate hNav1.2 gating or sensitivity to ProTx-II, this region may yet 
play a functional role in modulating other Nav channel isoforms. 
The S5-S6 loop in domain II of hNav1.2 contains an anchoring point for hβ2 
Although previous work has postulated the involvement of the domain II 
(DII) S5-S6 pore loop as the region responsible for forming an inter-subunit 
disulfide bond between particular Nav channel isoforms and β2 or β4 [144, 267], 
the precise residue has remained elusive. To explore the possibility of an hβ2 
anchoring point in this region, we individually replaced each of the three 
cysteines found here (910Cys, 912Cys, and 918Cys) with Ser. When expressed 
without or with WT hβ2, the C910S mutant exhibits the same degree of inhibition 
by 100 nM ProTx-II, indicating that the protective effect of hβ2 is lost and that 
910Cys is a critical residue for hβ2 binding (Fig. 3-7A and B, Fig. 3-8, and Table 3-
3). In contrast, the C918S mutant retains protection from 100 nM ProTx-II by the 
β-subunit. The C912S mutant displays a split toxin-sensitive population that is 
consistently observed throughout multiple oocyte batches. One fraction of 
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experiments reveals hNav1.2 current inhibition as though no hβ2 is present 
whereas another displays protection against 100 nM ProTx-II, similar to the WT 
channel and C918S mutant (Fig. 3-7A). To verify the presence of hβ2, oocytes 
were collected after recording and checked for expression by Western blot (see 
Figure 3-7B), thereby indicating that the observed loss-of-protection effects 
indeed relate to the hNav1.2 mutation. 
Altogether, these results hint towards a possibility of mutation-induced 
shifts in intra-subunit disulfide bond formations, a plausible scenario given the 
close vicinity of 910Cys, 912Cys, and 918Cys in hNav1.2. To evaluate this 
hypothesis, we constructed a set of double Cys to Ser mutations (C910S C912S, 
C910S C918S, and C912S C918S) and examined the effects on ProTx-II 
susceptibility without and in the presence of hβ2 (Fig. 3-7A and B, Fig. 3-8, and 
Table 3-3). According to previous work with rNav1.2a, mutating 912Cys or 918Cys 
results in a bridge between 910Cys and the remaining intact cysteine [268]. These 
experiments were carried out without a β2 subunit and with GVIIJ [267], a unique 
μO§-conotoxin that directly competes for binding to 910Cys; however, the rest of 
its binding site remains unexplored. In our hands, high concentrations of GVIIJ 
are needed to achieve an effect, and efficacy towards hNav1.2 is augmented in 
case of the C910S mutation (Fig. 3-9, Table 3-4), two complicating factors that 
made us revert to ProTx-II which is more potent and has clearly delineated 
binding sites within Nav1.2. Our experiments on these double mutants show a 
much clearer picture wherein hβ2 only protects against ProTx-II when 910Cys is 
intact: the C912S C918S mutant still has lowered toxin susceptibility whereas 
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C910S C912S and C910S C918S are completely inhibited by 100 nM ProTx-II, 
suggesting that these mutants no longer bind hβ2 (Fig. 3-7A and B, Fig. 3-8). 
Altogether, these results indicate that 910Cys is the disulfide bond partner of 55Cys 
in hβ2, while 912Cys and 918Cys could form an intra-subunit bridge. At first sight, 
the C912S data which show the split population appear in conflict with this 
interpretation. However, it is conceivable that losing the 912Cys- 918Cys bond 
results in the formation of a non-native bond between 910Cys and 918Cys (Fig. 3-
7C). Indeed, when 918Cys is mutated in addition to 912Cys, 918Cys again allows 
toxin protection by hβ2 similar to WT, suggesting it has become available again. 
The data also indicate that a non-native disulfide bond between 910Cys and 
912Cys may not occur in the C918S mutant, likely because such a Cys-Val-Cys 
disulfide bond could be too constrained. Importantly, hβ2 cannot protect the 
C910S C918S or the C910S C912S mutants from 100 nM ProTx-II, indicating 
that neither 912Cys nor 918Cys can compensate for the loss of 910Cys (Fig. 3-7C). 
To biochemically verify that Nav1.2 and β2 are covalently bound, we 
expressed the closely related and well-expressing rat variants (∼99% sequence 
identity) in oocytes and immunoprecipitated the rNav1.2a/rβ2 complex. It is worth 
noting that WT myc-tagged rβ2 can form higher-order oligomers under non-
reducing conditions, which may complicate the interpretation of immunoblots 
(Fig. 3-10). However, these oligomers disappear upon removal of 55Cys, further 
highlighting the reactivity of this residue. Notwithstanding this phenomenon, 
probing crude cell lysates uncovers a clear co-migration of myc-tagged rβ2 with 
rNav1.2a under non-reducing conditions, since co-expression yields a distinct 
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myc-stained band above the highest rβ2 oligomer (Fig. 3-11). Substitution of 
either 55Cys in rβ2 or 910Cys in rNav1.2a with Ser results in the loss of this 
covalent complex. Furthermore, the presence of DTT completely abolishes the 
rβ2-rNav1.2a complex as well as the rβ2 oligomers (Fig. 3-11B). Thus, these 
results confirm our toxin experiments and suggest the formation of a disulfide 
bond between 910Cys in the DII S5-S6 linker of Nav1.2 and 55Cys in β2. In 
addition to investigating the interaction of rNav1.2a and rβ2 in crude lysate from 
injected oocytes, we also pulled down rβ2 with an antibody directed against the 
C-terminal myc-tag and treated with DTT before loading onto a tris-acetate gel 
(Fig. 3-11C). In this experiment, we observe that WT rNav1.2a is present only 
when co-expressed with WT rβ2. Moreover, both 910Cys within the channel and 
55Cys in rβ2 are required for co-immunoprecipitation, thereby pointing to their role 
in forming a disulfide bond between both subunits (Fig. 3-5, Fig. 3-7). 
Next, we were curious to learn whether 910Cys also constitutes an inter-
subunit anchoring point for 58Cys in the β4-subunit. To examine this notion, we 
measured ProTx-II susceptibility of rNav1.2a and its C910S mutant expressed in 
oocytes without or with the rβ4-subunit (Fig. 3-12A and B, Table 3-5). Analogous 
to hβ2, we observe rβ4 protein production in oocytes (Fig. 3-12C) where it is able 
to influence the degree of rNav1.2a current inhibition by ProTx-II. In particular, 
100 nM ProTx-II reduces rNav1.2a conductance to ∼22% of peak whereas the 
current remaining in the presence of rβ4 is ∼55% of peak conductance. Other 
gating parameters such as G–V and channel availability relationships are 
unaffected. In case of the C910S mutant, the presence of rβ4 no longer 
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decreases ProTx-II efficacy (from ∼22% current inhibition to ∼17%, respectively, 
Table 3-5), thus illustrating the likely role of rNav1.2a 910Cys in forming a disulfide 
bond with rβ4 58Cys. In concert, (co-)immunoprecipitation experiments with 
rNav1.2a and rβ4 expressed in oocytes indicate that both partners are covalently 
bound and that mutating 910Cys in the channel indeed disrupts the disulfide bond 
(Fig. 3-11). 
Aligning the primary sequences of all tetrodotoxin (TTX)-sensitive hNav 
channel isoforms (Nav1.1–1.7) reveals that the cardiac hNav1.5 channel lacks 
the cysteine triad while the flanking sequences are highly conserved (Fig. 3-13A). 
Subsequently, it seems unlikely that hNav1.5 forms a covalent bond with hβ2, 
unless it occurs via a distinct site. However, when applying 100 nM ProTx-II to 
hNav1.5 without and with the β-subunit, we observe no effects on gating or 
protection against the toxin, suggesting that hβ2 may not modulate this channel 
isoform (Fig. 3-13B-E, Table 3-6). It is worth mentioning that hNav1.8 and 
hNav1.9, two TTX-resistant isoforms that are evolutionary related to hNav1.5, 
also lack the cysteine triad and may therefore not interact with hβ2 via a disulfide 
bond. 
 
Positioning β2 in relation to Nav1.2 
Having identified 910Cys within the DII S5-S6 loop of hNav1.2 and 55Cys 
within hβ2 as inter-subunit disulfide bond partners, we sought to find evidence for 
a potential locus of the β-subunit in relation to the channel. Although hβ2 seems 
to be anchored to the DII pore forming region, ProTx-II was previously shown to 
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target VSDs I, II, and IV [31], suggesting that the protective effect of hβ2 is 
through occlusion of the ProTx-II binding site in one or more of these regions. In 
order to determine which one, we assembled a set of animal toxins that, 
together, interact with VSDI, II, and IV in Nav1.2 [31], and tested whether or not 
their function is influenced by hβ2 (Fig. 3-14A). A previous study in which 
rNav1.2a S3b-S4 paddle loops from each domain (I-IV) were transplanted into a 
homotetrameric Kv channel to identify the VSDs with which toxins interact [31], 
found that the tarantula toxin PaurTx3 and scorpion toxin AahII [269] exclusively 
target VSDII and VSDIV, respectively. In addition, the tarantula toxins ProTx-I 
and ProTx-II both interact with the voltage sensor in DII and DIV, whereas ProTx-
II also binds to DI with high affinity. Here, we tested these four toxins on hNav1.2 
without and with hβ2 to determine if the presence of the subunit impacts toxin 
function. Aside from ProTx-II, we observe no significant difference in PaurTx3, 
AahII, or ProTx-I effect which suggests that hβ2 does not impede binding of 
these toxins to VSDII and VSDIV (Fig. 3-14B and C, Fig. 3-15, and Table 3-7). 
Therefore, we speculate that hβ2 primarily influences VSDI and as such, is 
located near this region (Fig. 3-14D). Since μO§-conotoxin GVIIJ function is also 
influenced by hβ2 [267], it will be interesting to investigate a possible VSDI 
binding site for this toxin. While our data are limited by the absence of VSDI- and 
VSDIII-specific toxins and do not exclude the possibility of non-overlapping 
binding sites for a particular toxin and hβ2 on the same VSD, or of direct 
competition for binding to the DII S5-S6 loop, they may yet prove valuable as 




The goal of this study was to explore the interaction of β2 with Nav1.2 and 
identify anchoring residues in both partners which will help orient functional 
motifs within their extracellular domains. Although we obtained the first crystal 
structure of the hβ4 extracellular region [260], the second reported structure of 
the corresponding hβ3 domain [146] highlights the unique character of each β-
subunit isoform. Since the ability to compare the distinct organizational features 
of β-subunits will provide valuable information as to their difference in action, we 
now obtained detailed structural information for the extracellular domain of hβ2 at 
a resolution of 1.35 Å (Fig. 3-1A and B, Table 3-1). We identified a flexible loop 
formed by 72Cys and 75Cys that is a unique feature among β-subunits but with a 
function that has yet to be elucidated (Fig. 3-1C, Fig. 3-2, and Fig. 3-5). 
Moreover, hβ2 contains a Cys at position 55 that, when mutated, disrupts the 
influence of hβ2 on hNav1.2 toxin pharmacology (Fig. 3-5B-D). Next, we 
combined mutagenesis and biochemical studies with spider and scorpion toxins 
that target specific VSDs within Nav1.2 [31, 78] to probe the interaction with hβ2. 
As a result, we found that 55Cys forms a distinct disulfide bond with 910Cys 
located in the domain II S5-S6 loop of hNav1.2, thereby revealing a 1:1 
stoichiometry (Fig. 3-7A and B, Fig. 3-8, and Table 3-3). We also exploited this 
toxin-reporter approach to investigate the possibility of intra-subunit disulfide 
bond formations between 910Cys, 912Cys, and 918Cys in hNav1.2, three reactive 
residues that are in close vicinity to each other. The outcome of these 
experiments indicates that 912Cys and 918Cys form an intra-subunit bridge in WT 
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hNav1.2 (Fig. 3-7). When mutating 918Cys, hβ2 still interacts with 910Cys whereas 
substituting 912Cys suggests the possibility for bond formation between 910Cys 
and 918Cys (Fig. 3-7C). 
Interestingly, hNav1.5 lacks these three cysteines (Fig. 3-13A) and as a 
result, ProTx-II is equipotent without or in the presence of hβ2 (Fig. 3-13B-E, and 
Table 3-6) This outcome provides evidence that this particular β-subunit may not 
modulate hNav1.5 in heterologous systems or that binding occurs through a 
different mechanism in native tissues. In concert, immunocytochemical studies in 
the heart and electrophysiological measurements in mammalian cell lines or 
oocytes disagree on whether hβ2 can modulate hNav1.5 function [154, 170, 270-
272]. As opposed to native cardiomyocytes, hNav1.5 may not associate with hβ2 
upon heterologous expression, a hypothesis that is supported by co-localization 
experiments in HEK293 cells where hNav1.5 and hβ2 were mainly found in the 
endoplasmatic reticulum or plasma membrane, respectively [271]. 
So far, none of the hβ2 mutations implicated in disorders have been found 
close to 55Cys, as they are located either in the signal peptide or near the 
transmembrane region [196-200]. In contrast, amino acid substitutions in the DII 
S5-S6 pore loop of particular Nav channel variants are linked to diseases. For 
example, more than 30 mutations have been identified within this region in 
hNav1.1, several of which relate to Dravet syndrome [2]. This includes C927F 
(corresponding to 918Cys in hNav1.2), and other variants which introduce an 
additional Cys that may interfere with local disulfide bond pattern formation. 
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Therefore, it is conceivable that DII S5-S6 linker mutations may affect channel 
interactions with hβ2 or hβ4. 
Collectively, our results uncover the disulfide link between hβ2 and 
hNav1.2 which opens up the possibility to assign a potential orientation of this 
subunit in relation to the channel and provide an experimental basis for future 
docking efforts (Fig. 3-14D). hβ2 may position itself in the gaps between VSDs 
where it can interact with a voltage sensor as well as anchor to a pore-forming 
region. One important observation from bacterial Nav channel crystal structures 
[16, 17, 45, 46] is the domain-swapped architecture of the channel in which the 
S1-S4 VSD within one subunit is located adjacent to the S5-S6 segments of the 
next subunit. Such a structural clockwise arrangement has also been consistently 
observed in prokaryotic and mammalian Kv channels [44, 48]. Since hNav 
channels may be organized in a similar fashion, the determinants of hβ2-subunit 
sensitivity can be located in multiple Nav channel domains. For example, we 
found that hβ2 binds to 910Cys in the S5-S6 loop of DII and influences ProTx-II 
interaction with VSDI. Although it is challenging to pinpoint its precise location, 
our data suggest that hβ2 is positioned in the cleft between VSDIV and VSDI or 
VSDI and VSDII where it is presented with an opportunity to interact with both 
determinants to influence ProTx-II action (Fig. 3-14D). In contrast, the consistent 
picture emerging from the literature is that Nav channel fast inactivation and 
voltage-dependence of activation changes substantially when co-expressed with 
the β1-subunit in heterologous systems [151, 152, 160, 161]. Given the pivotal 
role of VSDIV in channel fast inactivation [31-35], β1 may be positioned close to 
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VSDIV where it can also interact with the extracellular S5-S6 pore-loop within DI 
(Fig. 3-14D), a presumed interacting region [150, 151]. Altogether, this model 
suggests that particular Nav channel isoforms can interact simultaneously with a 
β1- and β2-subunit [9]. Future experiments will further investigate the possible 
locations of β3 and β4 in this model as well as allow the incorporation of 
mutational effects which is essential to uncover the contribution of β-subunit 
mutations to human disorders or contribute to small molecule screening efforts 




Materials and methods 
Production of the hβ2 extracellular domain 
Human β2 (residues 30–153) was cloned into a modified pET28 vector 
(pET28HMT) [273]. Mutations (C55A and C55/72/75A) were introduced using the 
Quikchange kit from Agilent Technologies (USA) according to the manufacturer’s 
instructions. Proteins were expressed at 18°C in E. coli Rosetta (DE3) pLacI 
strains (Novagen, USA), induced at an OD600 of ∼0.6 with 0.4 mM IPTG, and 
grown overnight prior to harvesting. Cells were lysed via sonication in buffer A 
(250 mM KCl and 10 mM HEPES at pH 7.4), supplemented with 25 µg/ml 
DNaseI and 25 µg/ml lysozyme. After centrifugation, the supernatant was applied 
to a PorosMC column (Tosoh Biosep, USA), washed with buffer A plus 10 mM 
imidazole, and eluted with buffer B (250 mM KCl plus 500 mM imidazole pH 7.4). 
The protein was dialyzed overnight against buffer A and cleaved simultaneously 
with recombinant TEV protease. Next, the samples were run on another 
PorosMC column in buffer A, and the flowthrough was collected and dialyzed 
against buffer C (10 mM KCl plus 10 HEPES at pH 7.4), applied to a HiloadQ 
column (GE Healthcare, USA), and eluted with a gradient from 0% to 30% buffer 
D (1 M KCl plus 10 mM HEPES at pH 7.4). Finally, the samples were run on a 
Superdex200 (GE Healthcare, USA) gel filtration column in buffer A. The protein 
samples were exchanged to 50 mM KCl plus 10 mM HEPES (pH 7.4), 
concentrated to ∼5 mg/ml using Amicon concentrators (3K MWCO; Millipore 




Crystallization, data collection, and structure solution 
Crystals were grown using the hanging-drop method at 4°C. Both C55A 
and C55/72/75A were crystallized in 0.1 M Tris (pH 8), 15–20% (w/v) PEG 6000. 
Crystals were flash-frozen after transfer to the same solution supplemented with 
30% glycerol. The data used to solve the final structures were collected at the 
Canadian Light Source (Saskatoon) beamline 08ID-1 and datasets were 
processed using XDS [239] and HKL3000 [274]. A search model was created by 
using only β-strands from PDB 4 MZ2, and with all side chains truncated to 
alanine. Molecular replacement was performed using Phaser [240], yielding poor 
initial phases which were improved via autobuilding in ARP/wARP [241]. The 
model was completed by successive rounds of manual model building in COOT 
[275] and refinement using Phenix [276]. A simulated annealing composite omit 
map was calculated with CNS [244] to verify the absence of residual model bias. 
85Met was found to be in a disallowed region of the Ramachandran plot in both 
structures. All structure figures were prepared using PYMOL (DeLano Scientific, 
San Carlos, USA). 
Accession codes 
Coordinates and structure factors have been deposited in the Protein Data 
Bank under accession codes 5FEB (C55A) and 5FDY (C55/72/75A). 
Toxin acquisition and purification 
ProTx-I and ProTx-II were acquired from Peptides International (USA), 
PaurTx3 from Alomone Labs (Israel). AaHII from Androctonus australis hector 
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venom was purified as described [269]. Toxins were kept at -20°C and aliquots 
were dissolved in appropriate solutions containing 0.1% BSA. 
Two-electrode voltage-clamp recording from Xenopus oocytes 
The DNA sequence of hNav1.2 (NM_021007.2), rNav1.2a 
(NM_012647.1), rβ4 (NM_001008880) and hβ2 (NM_004588.4) (acquired from 
Origene, USA), as well as their mutants was confirmed by automated DNA 
sequencing and cRNA was synthesized using T7 polymerase (mMessage 
mMachine kit, Ambion) after linearizing the DNA with appropriate restriction 
enzymes. Channels were expressed in Xenopus oocytes together with a β-
subunit (1:5 molar ratio) and studied following 1–2 days incubation after cRNA 
injection (incubated at 17°C in 96 mM NaCl, 2 mM KCl, 5 mM HEPES, 1 mM 
MgCl2 and 1.8 mM CaCl2, 50 μg/ml gentamycin, pH 7.6 with NaOH) using two-
electrode voltage-clamp recording techniques (OC-725C, Warner Instruments) 
with a 150 μl recording chamber. The data were filtered at 4 kHz and digitized at 
20 kHz using pClamp 10 software (Molecular Devices, USA). Microelectrode 
resistances were 0.5–1 MΩ when filled with 3 M KCl. The external recording 
solution contained 100 mM NaCl, 5 mM HEPES, 1 mM MgCl2 and 1.8 mM CaCl2, 
pH 7.6 with NaOH. The experiments were performed at room temperature 
(∼22°C) and leak and background conductances, identified by blocking the 
channel with tetrodotoxin (Alomone Labs, Israel), have been subtracted for all 
Nav channel currents. All chemicals used were obtained from Sigma-Aldrich 




Analysis of channel activity and toxin–channel interactions 
Voltage–activation relationships were obtained by measuring steady-state 
currents and calculating conductance (G), fitted to the data according to: G/Gmax 
= (1 + e−zF(V – V1/2)/RT)−1 G/Gmax = 1 + e-zF(V - V1/2)/RT-1  where G/Gmax is 
the normalized conductance, z is the equivalent charge, V1/2 is the half-activation 
voltage, F is Faraday's constant, R is the gas constant and T is temperature in 
Kelvin. Occupancy of closed or resting channels by ProTx-II and other toxins was 
examined using negative holding voltages where open probability was very low, 
and the fraction of uninhibited channels (Fu) was estimated using depolarizations 
that are too weak to open toxin-bound channels, as described previously. After 
addition of the toxin to the recording chamber, the equilibration between the toxin 
and the channel was monitored using weak depolarizations typically elicited at 5 
s intervals. Off-line data analysis was performed using Clampfit 10 (Molecular 
Devices, USA), and Origin 8 (Originlab, USA). 
Qualitative biochemical assessment of hβ2 production in Xenopus oocytes 
After each electrophysiological experiment, oocytes expressing hNav1.2, 
hβ2, and the described mutants were washed with ND100 and incubated with 0.5 
mg/ml Sulfo-NHS-LC-biotin (Pierce, USA) for 30 min. Oocytes were thoroughly 
washed again in ND100 before lysis (by pipetting up and down) in 20 μl/oocyte 
buffer H (1% Triton X-100, 100 mM NaCl, 20 mM Tris-HCl, pH 7.4) plus protease 
inhibitors (Clontech, USA). All subsequent steps were performed at 4°C. Lysates 
were gently shaken for 15 min after which they were centrifuged at 16,200 x g for 
3 min. The pellet was discarded and the supernatant (SN) transferred to a fresh 
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1.l Eppendorf tube. 40 μl of SN was stored at -80°C for later use as the whole cell 
protein aliquot. 200 μl of hydrophilic streptavidin magnetic beads (New England 
Biolabs, USA) were then added and the sample shaken gently at 4°C overnight. 
Beads were washed 6 times with buffer H and resuspended in 40 μl buffer H, 
after which the biotinylated protein was dissociated from the beads through the 
addition of 1X LDS loading buffer plus reducing agent (10% 2-ME, 50 mM DTT 
final conc.) and boiling at 95°C for 5 min to generate the surface protein fraction. 
All samples were appropriately diluted in buffer H to give equal protein 
concentrations, as measured by a BCA assay (Pierce, USA). 10 μg of the SN 
was run on a 10% Tris-Glycine Novex Mini-Gel (Thermo Fisher Scientific, USA) 
with Tris-Glycine running buffer and analyzed by Western analysis. Nitrocellulose 
membranes were probed overnight at 4°C with 1:1000 mouse anti-myc antibody 
as primary (Cell Signaling Technologies, USA) and for 45 min at room 
temperature with 1:10000 goat anti-mouse HRP-conjugated antibody as 
secondary (Thermo-Fisher Scientific, USA). Membranes were incubated for 5 
min with an enhanced chemiluminescent substrate before imaging. 
Immunoprecipitation of the Nav1.2/β2 complex 
Xenopus oocytes were injected with 5 ng RNA of rβ2, rNav1.2, or both 
(∼1:5 molar ratio) and incubated for 48 hr at 17°C. 30 oocytes were lysed for 
each condition, using 20 μl lysis buffer (1x PBS, 1% DDM, 10% glycerol, 1 mM 
EDTA, 1X protease inhibitor cocktail [Clontech, USA]) per oocyte, and 
homogenized by passing through a 25-gauge syringe [277]. The lysate was 
rotated for 1 hr at 4°C in a 1.5 ml microfuge tube, after which it was spun for 30 
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min at 20,000 x g at 4°C. Subsequent steps were performed at 4°C or on ice and 
during all rotations the tube was sealed with parafilm to prevent leakage. A fresh 
pipette tip was gently swirled in the supernatant to remove the bulk of the white 
goop by adhering to the tip and supernatant was transferred to a new tube, 
taking care not to disturb the pellet. The new tube was spun 3 min at 20,000xg 
and again was swirled with a fresh pipette tip to remove the white goop, after 
which the clear supernatant was transferred to a new tube. Protein concentration 
was assayed using a BCA protein concentration kit (Pierce, USA). 150 μg protein 
was brought to 150 μl in lysis buffer and 1.5 μg (1.5 μl of 1 mg/ml) anti-myc 
mouse antibody (Thermo-Fisher Scientific, USA) was added. The tube was 
rotated overnight at 4°C after which 30 μl protein G-coated magnetic Dynabeads 
(Thermo-Fisher Scientific, USA) were added and rotated for 4 hr at 4°C. The tube 
was spun for 1 min at 20,000xg and placed on a magnetic rack for 1 min to 
collect the beads. Supernatant was removed and stored for optimization and 
troubleshooting purposes, as were subsequent washes. The beads were washed 
with 200 μl wash buffer (1x PBS, 0.4% DDM, 10% glycerol, 1 mM EDTA) by 
pipette mixing and then magnetized to collect beads. The wash process was 
repeated three times. After the third wash, beads were suspended in 100 μl wash 
buffer, transferred to another tube, spun for 1 min at 20,000xg, and magnetized 
to collect beads. The tube was then spun again for 1 min at 20,000xg and 
magnetized, followed by removal of the last residual fluid. Protein was eluted in 
30 μl elution buffer (50 mM glycine, pH 2.8) by incubating for 3 min at room 
temperature, followed by magnetization and transfer to the final tube. For 
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Western blotting of the immunoprecipitate, 17 μl of eluate was combined with 2.5 
μl 10X reducing agent (Thermo-Fisher Scientific, USA) and 6.5 μl 4X LDS 
sample loading buffer (Thermo-Fisher Scientific, USA), heated for 10 min at 
37°C, then loaded onto a 1.0 mm 12-well 3–8% Novex Tris-Acetate pre-cast gel 
(Thermo-Fisher Scientific, USA). A rabbit anti-PanNav antibody (Alomone labs, 
Israel) and rabbit anti-hβ2 antibody (Cell Signaling Technologies, USA) were 
chosen to avoid cross-reaction of the Western blot secondary antibody against 
the mouse antibody used for immunoprecipitation. For Western blotting, the 
primary antibodies were used at 1:200 and 1:1000 dilutions, respectively, applied 
for 1 hr at room temperature and incubated for 45 min at room temperature with 
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Figure 3-1: Crystal structure of hβ2. (a) Cartoon representation of the hβ2 
(C55A) extracellular domain crystal structure, showing β strands in gold and 310 
helices in red. Cysteine side chains, as well as the 55Ala residue, are shown in 
stick representation. Positions of N-terminus (N) and C-terminus (C) are 
indicated. The loop containing the 72Cys- 75Cys disulfide bond is modeled in a 
dual conformation. (b) Detail of the dual conformation of the loop, showing all 
side chains in stick conformation. (c) Detail of the same loop in the C72A/C75A 
(C55A) mutant, shown from the same viewpoint as in panel (b). (d,e) Comparison 
of the surfaces of hβ2 (d) and hβ4 (e) surrounding the reactive cysteines (55Cys 
and 58Cys, respectively). Side chains of hydrophobic residues are shown in 
green, negatively charged carboxyl groups in red, and positively charged amino 
and guanidinium groups in blue. The position of the cysteine (which has been 
mutated to alanine to allow crystallization) is shown in yellow. (f) Size exclusion 
chromatograms (Preparative Superdex200) for hβ2 C55A and hβ2 C55/72/75A, 










Figure 3-2: Structural comparison of hβ2 to hβ3 and hβ4. (a) Superposition 
of the crystal structures of hβ2 C55A (gold) and hβ4 C58A (blue) in cartoon 
representation. Cysteines or their equivalent residues (A55 and A58, 
respectively) are shown in sticks. The major differences are highlighted in the 
figure. (b) Superposition of crystal structures of hβ2 C55A (gold) and hβ3 (red). 
(c) Root-mean-square-deviation (RMSD) plots showing the RMSD values per 
residue for hβ4 C58A (left, blue plot) and hβ3 (right, red plot) relative to hβ2 after 
a superposition. The residue numbers below correspond to the hβ2 numbers. 
Sections for which there are no corresponding residues at indicated with dotted 
lines. (d,e) Shown are sequence alignments of the extracellular domains of (d) 
hβ2 versus hβ4 and (e) hβ2 versus hβ3. Conserved residues are highlighted in 
grey, and cysteines in yellow. Observed disulfide bonds are also labeled (S-S). 







Figure 3-3: ProTx-II does not bind directly to β4. Isothermal calorimetry (ITC) 
experiments showing titration of 400 μM WT hβ4 extracellular domain into 40 μM 






Figure 3-4: G-V and SSI relationships for hβ2 mutants. (a) Conductance-
voltage (G-V, filled circles) and steady-state inactivation (SSI, open circles) 
relationships before 10nM ProTx-II addition are indicated in black and red in the 
presence of toxin. (b) Representative traces at -15 mV (holding potential of -
90 mV) for the corresponding graphs seen in (a). Scale bar is 10 ms along 
horizontal axis and displayed nA along the vertical axis. (c) Western blot showing 
that the C72A C75A hβ2 mutant is expressed in whole cell (filled circle) and 
surface (open circle) fractions either alone (middle column) or with hNav1.2 (right 
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Figure 3-5: Effect of hβ2 on hNav1.2 toxin pharmacology. (a) Co-expression 
of hNav1.2 with hβ2 decreases the degree of inhibition by 100 nM ProTx-II. Left 
trace shows ProTx-II strongly inhibiting WT hNav1.2 whereas right trace displays 
attenuated inhibition in the presence of hβ2. Black trace is control condition 
without toxin, red is in the presence of ProTx-II. Traces depict a 50 ms 
depolarization to -15 mV from -90 mV. Scale bar is 10 ms on horizontal axis and 
given nA vertically. (b) Normalized conductance-voltage (G-V, filled circles) and 
steady-state inactivation (I-V, open circles) relationships for hNav1.2 with and 
without hβ2. Pre-toxin values are shown in black and post-toxin in red. Fit values 
can be found in Table 3-2. (c) Dot plot comparing hβ2 mutations by ability to 
prevent ProTx-II inhibition of hNav1.2. Black circles represent individual oocytes; 
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vertical axis shows percent of inhibition by ProTx-II at peak conductance. Blue 
lines represent a 95% confidence interval. hβ2 mutations are presented 
underneath the horizontal axis and label the lanes below in (d). Statistical 
significance (p < 0.01) is indicated by an asterisk. (d) Western blot against the C-
terminal myc-tag of hβ2. No signal is seen in the negative control but is observed 







Figure 3-6: Amino acid sequence alignment of the β2 protein found in 
various organisms. Conserved cysteines 72Cys and 75Cys in hβ2 are indicated 
with a grey background. Residue numbers in hβ2 above sequences are shown 
as a reference. Protein accession numbers for sequences used are:  
H. sapiens (NP_004579.1),  
P. abelii (XP_002822587.1),  
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M. davidii (XP_006761624.1),  
E. fuscus (XP_008148335.1),  
S. harrisii (XP_003764204.1),  
T. guttatus (XP_010214560.1),  
C. brachyrhynchos (XP_008635161.1),  
F. albicollis (XP_005058672.1),  
A. canadensis (XP_011600162.1),  
M. vitellinus (XP_008927155.1),  
A. carolinensis (XP_003229016.2),  
P. bivittatus (XP_007424304.1),  
X. tropicalis (NP_001116903.2),  






Figure 3-7: hβ2 forms a disulfide bond with 910Cys in hNav1.2. (a) Dot plot 
showing degree of hNav1.2 mutant inhibition by 100 nM ProTx-II, with and 
without hβ2. Black circles represent single oocytes expressing the indicated 
constructs and currents were measured at peak conductance. Blue bars indicate 
95% confidence interval, and the red bars are 95% confidence intervals for both 
populations in the C912S mutant co-expressed with hβ2. Statistical significance 
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with p < 0.01 is shown by an asterisk. (b) Western blot against a myc-tag reveals 
the presence of hβ2 in whole cell fraction of oocytes co-injected with hβ2 mRNA. 
(c) Schematic depiction of the proposed disulfide arrangement in hNav1.2 
mutants with hβ2. hNav1.2 cysteines are displayed on the top arc with α (pore-
forming subunit), while 55Cys of hβ2 is on the bottom arc with β. Black lines 
represent putative disulfide bonds and dashed lines indicate alternate 
possibilities. Red X symbolizes a Cys to Ser mutation and an asterisk denotes 






Figure 3-8: G-V and SSI relationships for hNav1.2 mutants. (a) G-V (filled 
circles) and SSI (open circles) curves are plotted for each of the hNav1.2 Cys to 
Ser mutants with and without hβ2. Black indicates values before the addition of 
100 nM ProTx-II, red shows values after toxin treatment. In the presence of hβ2, 
the WT hNav1.2, the C918S mutant, and the C912S C918S all show a 
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diminished susceptibility to ProTx-II whereas the C912S mutant shows a mixed 
phenotype. (b) Sample traces illustrating the effect of 100 nM ProTx-II on 
hNav1.2 with and without hβ2 after depolarization to -15 mV from -90 mV. 
Degree of inhibition reflects the G-V and SSI data shown in (a). Horizontal arm of 






Figure 3-9: Activity of the μO§-conotoxin GVIIJ is affected by hβ2. (a) 
Representative traces of 5 μM GVIIJ affecting hNav1.2-mediated currents with 
and without hβ2 in Xenopus oocytes. Control traces are shown in black, red after 
treatment with 5 μM GVIIJ, and green after a 5-min washout with recording 
solution. Horizontal bar is 10 ms and vertical bar measures current in nA. The 
data illustrate that 5 μM GVIIJ can partially block hNav1.2 only when hβ2 is not 
present. (b) G-V (filled circles) and SSI (open circles) relationships detailing the 
effect of 5 μM GVIIJ on hNav1.2 with and without hβ2 across a wide voltage 
range. Color coding is the same as in (a). (c) Dot plot showing the effect of GVIIJ 
on hNav1.2 Cys to Ser mutants. Red circles indicate fraction of peak control 
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conductance after addition of 5 μM GVIIJ while green circles represent the same 
after a 5-min washout. Vertical bars show 95% confidence intervals for color-
matched circles. The data clearly illustrate a reduced sensitivity to GVIIJ in the 
presence of hβ2; however, the results are variable as discussed in the text and 






Figure 3-10: Biochemical assessment of rβ2 oligomer formation. Figure 
represents extended data found in Fig. 3-11. WT myc-tagged rβ2 can form 
higher-order oligomers under non-reducing conditions (indicated with an open 
arrow in the middle lane). These oligomers disappear upon removal of 55Cys 
(right lane), further highlighting the reactivity of this residue. Left lane represents 






Figure 3-11: Biochemical verification of the β2 and β4 disulfide bond 
with 910Cys in Nav1.2. Top rows indicate particular Nav channel and β-subunit 
constructs with which oocytes were injected. WT proteins are indicated as such 
whereas mutants are noted with a residue number; a superscript letter 
symbolizes in which partner of the complex pair the mutation is found. rβ2 was 
loaded in each case except in the two rightmost lanes, where rβ4 was used. 
Labels on left column indicate which antibody was used to immunoblot the 
associated slice. (a) Western blot run under non-reducing conditions reveals a 
fraction of rβ2 migrating with WT rNav1.2a but not after selective cysteine 
substitution. Crude lysate from injected oocytes was run on a protein gel and 
probed for both the channel and the myc-tag of the β-subunit. The top PanNav 
slice and bottom myc slice show the expression of the respective proteins in 
lysates from oocytes injected with the indicated constructs. Even though equal 
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quantities of protein was loaded in each lane (10 μg), the C910S channel mutant 
expresses less bountifully than the WT channel and as a result shows a weaker 
signal. The WT β-subunit can form redox-sensitive multimers that migrate at an 
apparent mass similar to that of the Nav channel. Mutation of 55Cys prevents 
multimer formation and disappearance of the high molecular weight band. Open 
arrows identify bands representing Nav channel-bound β-subunit and aid in 
distinguishing them from the multimeric β-subunit. Substituting 910Cys within 
rNav1.2a with Ser causes a loss of the channel-bound β-subunit band. rβ4 also 
binds to WT rNav1.2a, as evidenced by a second band, and no longer interacts 
with the C910S mutant. (b) Addition of DTT prevents both binding of rβ2 to the 
channel and formation of β-subunit multimers. The absence of myc signal at the 
same apparent weight as rNav1.2a indicates that binding to the channel is 
sensitive to reduction. In all cases, α-tubulin was used as a loading control. (c) 
WT rNav1.2a co-immunoprecipitates with rβ2 and rβ4. The β-subunit was pulled 
down with an antibody directed against a C-terminal myc-tag and treated with 
DTT before loading onto the gel. The channel is present only when the WT 






Figure 3-12: Mutation of 910Cys in rNav1.2a disrupts rβ4 influence on ProTx-
II effect. (a) Replacement of 910Cys with Ser in rNav1.2a impairs the ability of rβ4 
to protect against 100 nM ProTx-II inhibition in a manner similar to that of hβ2. 
Co-expression of the rNav1.2a isoform with rβ4 minimizes ProTx-II inhibition 
compared to the channel expressed alone. Graphs compare G-V and SSI 
relationships, in filled and open circles, respectively. Black color is used for 
values before the addition of 100 nM ProTx-II and red after. (b) Dot plot 
comparing the degree of inhibition by 100 nM ProTx-II as a fraction of the pre-
toxin peak current. rβ4 confers a high level of a protection against ProTx-II 
inhibition which is absent in the C910S mutant. (c) Western blot directed against 
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Figure 3-13: ProTx-II inhibits hNav1.5 in the presence of hβ2. (a) Sequence 
alignment comparing TTX-sensitive hNav channels in the beginning of the S5-S6 
(SS1) loop. Green bar indicates the C-terminal portion of the DII transmembrane 
segment 5 (TM5), and gray background highlights the conserved cysteine triad. 
The hNav1.2 amino acid sequence is shown in red and hNav1.5 in blue. Residue 
number of the N-terminal Val for each channel is superscripted. (b) Dot plot 
showing that hNav1.5 is not protected against inhibition by 100 nM ProTx-II upon 
co-expressing hβ2. Black circles are individual oocytes of which sodium currents 
were measured at peak conductance and blue bars show 95% confidence 
interval. (c) Western blot probing for the C-terminal myc-tag of hβ2 reveals its 
presence in whole cell oocyte fractions. hNav1.5 sees no change in 100 nM 
ProTx-II effect in the presence of hβ2. (d, e) G-V (filled circles) and SSI (open 
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circles) relationships for hNav1.5 with and without hβ2. Black is used for values 
before ProTx-II addition and red after toxin application. Also shown are 
representative traces illustrating the lack of effect of hβ2 on hNav1.5 
susceptibility to 100 ProTx-II. Horizontal bar indicates 10 ms; vertical bar 






Figure 3-14: hβ2 influences hNav1.2 VSDI toxin pharmacology. (a) Cartoon 
illustrating the binding site of AaHII, PaurTx3, ProTx-I, and ProTx-II within the 
VSDs of Nav1.2. Binding to a particular VSD is indicated by coloration. (b) Dot 
plot showing percent of change in peak conductance for hNav1.2 after treatment 
by each toxin without or in the presence of hβ2. Blue bars represent 95% 
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confidence interval and statistical significance (p < 0.01) is noted by an 
asterisk. c) Western blot probing for the C-terminal myc-tag of hβ2, showing its 
presence in each experimental condition except the negative control. (d) Shown 
is a Nav channel illustration consisting of the four VSDs I-IV (S1-S4) and the 
corresponding pore-forming regions (S5-S6) in grey (DI, III, and IV) or orange 
(DII) in a clockwise orientation which fits with the data reported here. Such an 
orientation places a S1-S4 voltage sensor of one domain adjacent to the S5-S6 
region of the next. A/B (shades of blue) depicts a putative location of hβ2 in the 
complex where the subunit can interact with the S5-S6 pore region of DII as well 
as occlude the ProTx-II binding site on VSDI. In contrast, hβ1 (green) may 
position itself between VSDIV and VSDIII where it can interact with the S5-S6 






Figure 3-15: Activity of spider and scorpion toxins on hNav1.2. (a) G-V and 
SSI relationships for hNav1.2, with or without hβ2, treated with toxins (100 nM) 
with known binding sites. (a) G-V and SSI curves are provided for each of the 
four toxins tested. Black indicates control values and red illustrates toxin effect. 
Filled circles are used for G-V curves and open circles for SSI. (b) 
Representative traces after depolarization to -15 mV from -90 mV for each toxin 
tested on hNav1.2 with black indicating pre-toxin currents and red showing 
currents after toxin application. Horizontal scale bar indicates 10 ms whereas 







 C55A C55/72/75A 
Data collection   
Space group  P 3     P212121 P 1 
Cell dimensions   
    a, b, c (Å) 28.7, 59.4, 71.3 28.4,  36.2, 59.2 
 ()  90.0,  90.0, 90.0 89.9, 89.9, 76.4 

















I / I 20.36 (1.81) 14.94 (2.56) 
Completeness (%) 99.4 (96.2) 99.0 (90.1) 
Redundancy 14.08 (13.8) 
 
3.0 (1.6) 
Refinement   
Resolution (Å) 45.67 –1.35   30-1.85 
No. reflections 27,539 19,296 
Rwork / Rfree 16.75/19.25 14.18/19.20 
No. atoms   
    Protein 
 
    Ligand 





A:  1066 
B:  1065 
      6 
      404  
   
B-factors   
    Protein 
 




A:  16.4 
B:  16.5 
36.1 
    Water 42.9 29.8 
R.m.s. deviations   
    Bond lengths (Å) 0.019 0.007 
    Bond angles () 1.777 0.981 
Table 3-1: Data collection and refinement statistics. a One crystal for each 
structure was used for data collection and structure determination. b Values in 








Table 3-2: Table providing values for fits of the data presented in Figure 3-
4 and Figure 3-5. G-V and SSI relationship data were fitted by a Boltzmann 
curve. V1/2 provides the midpoint voltage of the calculated curve (in mV) and Vc 
the unit-less slope, with standard error of the mean (SEM). Right column shows 
peak conductance after toxin treatment as a fraction of untreated peak 
conductance with the upper and lower bounds of the 95% confidence interval in 





peak Gafter/peak Gbefore 











before -20.2 ± 0.2 5.5 ± 0.1 -37.3 ± 0.8 7.3 ± 0.6 
0.17 (0.13, 0.20) 
after  -2.3 ± 3.5  12.2 ± 0.8 -44.1 ± 2.2  13.3 ± 1.3 
+     
WT 
before -20.7 ± 0.1 5.5 ± 0.1 -38.0 ± 0.6 8.9 ± 0.6 
0.64 (0.50, 0.79) 
after -17.9 ± 0.6 5.9 ± 0.2 -39.8 ± 1.0 9.3 ± 0.6 
+2 
C55A 
before -24.0 ± 0.3 5.0 ± 0.1 -36.8 ± 0.8 7.6 ± 0.6 
0.19 (0.12, 0.26) 
after -12.8 ± 2.7 9.1 ± 0.8 -39.9 ± 1.4 9.4 ± 1.0 
+2 
C55S 
before -24.0 ± 0.5 5.2 ± 0.1 -39.7 ± 0.5 8.4 ± 0.4 
0.18 (0.13, 0.22) 




before -20.9 ± 0.2 5.3 ± 0.1 -37.7 ± 0.6 8.8 ± 0.5 
0.59 (0.47, 0.70) 




Table 3-3: Table providing values for fits of the data presented in Figure 3-
7 and Figure 3-8. G-V and SSI relationship data were fitted by a Boltzmann 
curve. V1/2 provides the midpoint voltage of the calculated curve (in mV) and Vc 
the unit-less slope, with standard error of the mean (SEM). Right column shows 
peak conductance after toxin treatment as a fraction of untreated peak 
 
activation inactivation 
peak Gafter/peak Gbefore 











before -20.7 ± 0.1 5.5 ± 0.1 -43.9 ± 0.8 9.3 ± 0.6 
0.14 (0.05, 0.23) 
after -6.2 ± 4.9  11.4 ± 1.4 -45.8 ± 1.7  12.7 ± 1.5 
+2 
before -21.7 ± 0.2 4.4 ± 0.1 -39.7 ± 1.0 7.8 ± 0.6 
0.71 (0.47, 0.94) 







before -20.7 ± 0.4 6.0 ± 0.2 -41.7 ± 0.5 9.6 ± 0.5 
0.16 (0.14, 0.19) 
after    1.3 ± 8.0  12.1 ± 1.4 -46.3 ± 1.2  14.9 ± 0.9 
+2 
before -18.3 ± 0.2 6.0 ± 0.1 -41.4 ± 0.7 9.2 ± 0.5 
0.17 (0.09, 0.24) 







before -23.8 ± 0.1  6.5 ± 0.1 -43.5 ± 0.7  10.0 ± 0.6 
0.26 (0.15, 0.37) 
after   -4.7 ± 10.3 14.3 ± 2.7 -57.2 ± 5.1 16.6 ± 340 
+2 
before -26.0 ± 0.5   5.3 ± 0.3 -41.0 ± 0.7 8.92 ± 0.5 
0.33 (0.26, 0.39) 







before -21.2 ± 0.5   5.8 ± 0.3  -36.8 ± 0.9   7.8 ± 0.6 
0.17 (0.12, 0.22) 
after >50 24.6 ± 6.5 -56.8 ± 12.9 16.1 ± 9.8 
+2 
before -21.3 ± 0.3  5.3 ± 0.1 -41.1 ± 1.0   6.7 ± 0.6 
0.54 (0.43, 0.65) 













before -22.6 ± 0.3  5.8 ± 0.1 -45.1 ± 0.8   9.1 ± 0.4 
0.14 (0.10, 0.18) 
after -9.2 ± 4.4 11.0 ± 1.0 -53.0 ± 1.9 13.1 ± 1.3 
+2 
before -21.7 ± 0.3  6.1 ± 0.2 -42.1 ± 0.5   9.9 ± 0.5 
0.32 (0.20, 0.44) 













before -15.7 ± 0.7  6.1 ± 0.4 -36.1 ± 0.7 10.2 ± 0.7 
0.24 (0.11, 0.37) 
after >50 19.5 ± 7.0 -38.2 ± 3.5 8.0 ± 2.9 
+2 
before -18.8 ± 0.3  6.3 ± 0.2 -43.0 ± 0.4 8.3 ± 0.3 
0.23 (0.11, 0.36) 













before -23.5 ± 0.4  5.6 ± 0.2 -43.7 ± 0.8  7.1 ± 0.7 
0.23 (0.15, 0.31) 
after -18.8 ± 2.5  9.4 ± 0.8 -48.0 ± 2.0  10.3 ± 1.5 
+2 
before -22.8 ± 0.4  5.3 ± 0.3 -41.9 ± 0.8 6.6 ± 0.7 
0.68 (0.60, 0.76) 
after -17.7 ± 1.9  8.1 ± 0.8 -45.1 ± 0.5 8.3 ± 0.5 
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conductance with the upper and lower bounds of the 95% confidence interval in 




Table 3-4: Table providing values for fits of the data presented in Figure 3-
9. G-V and SSI relationship data were fitted by a Boltzmann curve. 1/2 provides 
the midpoint voltage of the calculated curve (in mV) and Vc the unit-less slope, 
with standard error of the mean (SEM). Right column shows peak conductance 
after toxin treatment as a fraction of untreated peak conductance with the upper 
and lower bounds of the 95% confidence interval in parentheses, reflecting the 




peak Gafter/peak Gbefore 










before -30.9 ± 1.0 4.5 ± 0.3 -41.1 ± 1.7 6.7 ± 0.7 
0.59 (0.48, 0.71) 
after -24.1 ± 0.6 5.6 ± 0.2 -44.4 ± 1.1 8.7 ± 0.6 
recovery -31.2 ± 1.7 3.8 ± 0.4 -45.2 ± 1.0 8.7 ± 0.5 0.80 (0.61, 0.99) 
+2 
before -27.5 ± 0.5 4.3 ± 0.2 -44.1 ± 1.1 9.1 ± 0.7 
0.95 (0.87, 1.02) 
after -25.2 ± 0.2 4.5 ± 0.1 -43.9 ± 1.2 9.6 ± 0.9 




Table 3-5: Table providing values for fits of the data presented in Figure 3-
12. G-V and SSI relationship data were fitted by a Boltzmann curve. V1/2 provides 
the midpoint voltage of the calculated curve (in mV) and Vc the unit-less slope, 
with standard error of the mean (SEM). Right column shows peak conductance 
after toxin treatment as a fraction of untreated peak conductance with the upper 
and lower bounds of the 95% confidence interval in parentheses, reflecting the 




peak Gafter/peak Gbefore 











before -21.2 ± 0.2 6.4 ± 0.2 -39.9 ± 0.6 9.8 ± 0.6 
0.22 (0.08, 0.36) 
after -12.8 ± 0.8 9.4 ± 0.5 -42.4 ± 1.7 11.6 ± 1.7 
+4 
before -24.3 ± 0.4 7.3 ± 0.3 -47.6 ± 0.6 10.7 ± 0.6 
0.55 (0.49, 0.61) 







before -23.2 ± 0.3 6.6 ± 0.3 -44.6 ± 0.8 12.1 ± 0.9 
0.17 (0.02, 0.32) 
after -15.5 ± 0.6 9.9 ± 0.4 -47.5 ± 1.4 14.6 ± 1.6 
+4 
before -20.9 ± 0.4 6.5 ± 0.4 -47.1 ± 0.7 11.4 ± 0.7 
0.11 (0.05, 0.17) 




Table 3-6: Table providing values for fits of the data presented in Figure 3-
13. G-V and SSI relationship data were fitted by a Boltzmann curve. V1/2 provides 
the midpoint voltage of the calculated curve (in mV) and Vc the unit-less slope, 
with standard error of the mean (SEM). Right column shows peak conductance 
after toxin treatment as a fraction of untreated peak conductance with the upper 
and lower bounds of the 95% confidence interval in parentheses, reflecting the 





peak Gafter/peak Gbefore 











before -35.6 ± 0.4 5.9 ± 0.2 -67.8 ± 0.7 7.7 ± 0.4 
0.29 (0.22, 0.37) 
after -31.1 ± 0.8 7.3 ± 0.4 -65.0 ± 1.3 6.8 ± 0.8 
+2 
before -35.2 ± 0.5 5.9 ± 0.2 -70.3 ± 0.7 7.6 ± 0.4 
0.28 (0.15, 0.39) 




Table 3-7: Table providing values for fits of the data presented in Figure 3-
14 and Figure 3-15. G-V and SSI relationship data were fitted by a Boltzmann 
curve. V1/2 provides the midpoint voltage of the calculated curve (in mV) and Vc 
the unit-less slope, with standard error of the mean (SEM). Right column shows 
peak conductance after toxin treatment as a fraction of untreated peak 
conductance with the upper and lower bounds of the 95% confidence interval in 




peak Gafter/peak Gbefore 






before -16.1 ± 0.2 5.5 ± 0.1 -36.5 ± 0.7 7.1 ± 0.6 
1.74 (1.61, 1.88) 
after -24.7 ± 0.6 6.4 ± 0.2 -52.0 ± 1.2 6.7 ± 0.9 
+2 
before -11.8 ± 0.3 5.8 ± 0.1 -33.8 ± 0.3 9.7 ± 0.3 
1.68 (1.44, 1.93) 








before -16.0 ± 0.3 5.7 ± 0.1 -37.1 ± 0.7 7.3 ± 0.7 
0.63 (0.47, 0.78) 
after -15.7 ± 1.7 6.2 ± 0.5 -38.6 ± 0.5 8.3 ± 0.4 
+2 
before -12.2 ± 0.4 6.1 ± 0.2 -32.9 ± 0.6 8.8 ± 0.6 
0.65 (0.60, 0.70) 







before -16.6 ± 0.4 5.0 ± 0.1 -38.1 ± 0.7 7.4 ± 0.6 
0.17 (0.09, 0.26) 
after   -9.2 ± 3.0 7.8 ± 0.7 -42.2 ± 1.1 9.0 ± 0.6 
+2 
before -15.6 ± 0.6 5.1 ± 0.2 -34.2 ± 0.7 8.5 ± 0.5 
0.23 (0.17, 0.30) 







before -17.3 ± 0.5 5.4 ± 0.2 -39.3 ± 1.0 7.1 ± 0.6 
0.31 (0.20, 0.42) 
after   -9.3 ± 2.5 8.5 ± 0.7 -42.2 ± 0.7 9.6 ± 0.6 
+2 
before -21.4 ± 0.3 5.5 ± 0.2 -37.8 ± 1.1 6.8 ± 0.9 
0.77 (0.64, 0.90) 





ARCHITECTURE OF THE BETA2/BETA4-NAV CHANNEL  
SIGNALING COMPLEX 




Summary of findings 
The findings reported here pave the way for a better appreciation of Nav 
channel/β-subunit interaction and the functional consequences underlying their 
mutations. Through the tireless efforts of our collaborators, Samir Das and Filip 
Van Petegem, our group solved the crystal structures of the β2 and β4 subunits 
and, combined with knowledge of animal toxins, we were able to generate novel 
architectural insights into Nav channel/β-subunit interaction. The conclusions 
drawn from our work should provide a greater sense of context in which 
subsequent investigations can be pursued. 
β-subunits affect toxin pharmacology 
 Supporting prior suggestions [172, 213, 258], we demonstrated that β-
subunits can affect the toxin pharmacology of the Nav channel. We screened 
seven animal toxins (ProTx-I, ProTx-II, AaHII, TsVII, LqqIV, ATX-II, and β-PMTX) 
on the Nav1.2 channel co-expressed with each of the four β-subunits to evaluate 
the effects the β-subunit may have on toxin binding. We discovered that several 
of the β-subunits were able to affect toxin behavior. For example, the β1 subunit 
causes the α-scorpion toxin LqqIV to induce a depolarizing, leftward shift in the 
steady-state inactivation (SSI) curve whereas normally it would generate a 
hyperpolarizing, rightward shift. While the β-scorpion toxin TsVII normally evokes 
a hyperpolarizing shift in the conductance-voltage (G-V) curve and leaves 
maximal conductance unaffected, co-expression of the β4 subunit now causes a 
substantial decrease in maximal conductance in addition to the hyperpolarizing 
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shift. Most interesting to us was the discovery that both β2 and β4 could diminish 
Nav1.2 sensitivity to ProTx-II inhibition, a relationship we later exploited to 
determine both Cys residues involved in forming the disulfide bridge between 
Nav channel and β-subunit [260, 278].  
 Beyond the obvious outcome of providing us with novel tools to study β-
subunits, this finding brings to light a new means by which the β-subunit may 
influence the Nav channel; e.g. the possibility that β-subunits could complicate 
future applications of toxins as therapeutics. Several toxins derived from animal 
venom have found clinical use [279, 280], but it remains to be seen whether β-
subunits could play an antagonistic role, lowering efficacy by blocking their 
binding sites [259]. Alternatively, toxins could be used to displace mutant β-
subunits from the channel that could create disease states.  
Lastly, this discovery shows that we must take care when testing toxins on 
Nav channels in the presence of β-subunits. It is possible that a β-subunit could 
generate a unique phenotype a la TsVII with β4 that would spuriously suggest a 
unique effect of the toxin on a Nav channel isoform. Alternatively, β-subunits 
could diminish the sensitivity of the Nav channel to a toxin, erroneously reporting 
a lower affinity for the toxin than is actually the case. Even greater care must be 
taken when testing toxins in native tissue, where β-subunit expression may be 
uncertain and could drastically alter the outcome of experiments if the 





β2 and β4 bind to the Nav1.2 channel through 55Cys and 58Cys, respectively 
 Harnessing the unique ability of β2 and β4 to diminish ProTx-II inhibition of 
the Nav channel, we were able to identify the Cys residues of the β-subunit 
responsible for binding to Nav1.2. Initial experiments with DTT incubation 
revealed the link between β4 and Nav1.2 was sensitive to reduction and likely 
mediated through a disulfide interaction. Having observed in crystal structures 
the free cysteines 55Cys and 58Cys of β2 and β4, respectively, we mutated each 
to Ala (and Ser, in the case of 55Cys) and witnessed a dramatic loss of protection 
against ProTx-II. To verify that the disappearance of the β-subunit functional 
effect was not due to a disappearance of the β-subunit entirely, we verified that 
the C55A β2 and C58A β4 were both expressed and trafficked to the surface 
normally, but were otherwise unable to protect the channel against ProTx-II. We 
used a range of toxin concentrations to determine the IC50 of ProTx-II and saw 
that while the presence of WT β4 reduced affinity to the channel 5-fold, 
introduction of the C55A mutation restored toxin sensitivity of the Nav channel to 
a degree indistinguishable from that of the Nav channel expressed alone.   
 These results, examined in conjunction with β-subunit crystal structures, 
allow us to better assess the effect of disease-related β-subunit mutations on 
binding. For example, compromising the disulfide bond between Nav1.1 and β2 
has been shown to affect Nav complex targeting to nodes of Ranvier [144]. By 
examining how mutations change the local structure of the reactive cysteine, we 
derive an idea of how they might impact binding of the β-subunit with the Nav 
channel. In addition, subsequent investigations into the functional interface 
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between Nav channels and β2/β4 will be better able to orient the two proteins 
and observe how mutations might perturb the structural conformation. A 
preliminary depiction of this interaction is shown in Figure 4-1. 
 
Nav1.2 binds to β2 and β4 through 910Cys 
 
 Once we had identified the Cys residues of the β-subunits responsible for 
the disulfide bond with the Nav channel, we then took the next step of locating 
the corresponding Cys on the Nav channel. Employing the same ProTx-II-based 
assay used to find the β-subunit cysteine, we mutated a number of extracellular 
Cys residues of the Nav channel to Ser, targeting the DII S5-S6 region [144, 
267]. In doing so, we discovered that the DII S5-S6 C910S mutant of Nav1.2 
erased the capacity for β2 and β4 to protect the Nav1.2 against ProTx-II 
inhibition. To confirm this finding biochemically, we used Western blotting to 
demonstrate that the WT β2 and β4 subunits co-migrated with the WT Nav1.2 
channel. Further, we showed that mutations of the identified cysteines on the β-
subunit or the Nav channel prevented this co-migration. We then found that only 
with WT forms of the proteins could we co-immunoprecipitate the Nav channel 
with the β-subunit, providing further evidence of the interaction between those 
residues.  
 Having established 910Cys as the Nav1.2 site for β-subunit binding, we 
used several toxins with known binding sites (AaHII DIV, PaurTx3 DII, ProTx-I DII 
and DIV, ProTx-II DI, DII, and DIV) [31] to see if their effect was impacted by the 
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presence of the β2 subunit. In fact, only ProTx-II was affected, which would 
suggest a binding site for the β2 subunit adjacent to VSDI. This is consistent with 
the domain-swap architecture of the channel that would place the DII S5-S6 
adjacent to the DI voltage sensor.  
 These results suggest a shared binding site for β2 and β4 at 910Cys of 
Nav1.2, which has a number of implications for β-subunit physiology. Mutations 
near the 910Cys site could affect binding to the β-subunit and might be a 
causative disease mechanism for some Nav channel mutations in that region [2]. 
If the two subunits do, in fact, share a binding site, it would suggest that only one 
can be bound to the channel at a time, providing insight into β-subunit 
stoichiometry. Given that β2 KO mice are viable while the β4 KO is embryonically 
lethal, it would seem that their roles in health must either be exerted distant to the 
binding site or else are mediated elsewhere in the body. Additionally, this site is 
distinct from that suggested for β1, with the latter being located between DIII and 
DIV, based upon cross-linking studies showing an interaction with the DI and DIV 
pore loops [150, 151]. This is consistent with prior studies suggesting that both 
β1 and β2 can be simultaneously bound to the channel [9], and raises the 
question of why the body has expressed each β-subunit where it does. As the 
roles of β2 and β4 continue to be resolved, the idea of mutual exclusion at VSDI 






Avenues to study β-subunit disease mutations 
 
Previous investigations into the pathogenesis of β-subunit-related 
diseases had no recourse to structural knowledge but with the results of this work 
we are able to begin making strides into understanding the multidimensional 
consequences of mutations in the β-subunit. The first identified β-subunit disease 
mutant was C121W in β1, which leads to a form of epilepsy, generalized epilepsy 
febrile seizures plus (GEFS+) [188]. Despite linking this mutation to a disease, 
there is not yet a consensus on the mechanism [221-223]. We generated the 
corresponding mutant in β4, C131W, and found that a disulfide bond in the 
protein core was disrupted, thus destabilizing the β-subunit structure. In 
particular, we discovered that the local conformation surrounding the bridge-
forming 58Cys was altered and may have affected binding to the channel, 
explaining the loss of protection conferred by β4 against ProTx-II inhibition.  
Although we examined only a single mutant, we were able to map many 
more β1 mutations onto the β4 structure and the possibility exists that a similar 
approach could be used to determine their pathogenic mechanism. However, as 
three of the four β subunit structures have been solved already [146, 260, 278], it 
is only a matter of time before the β1 structure is too. With structures in hand, we 
have the ability to directly observe how mutations may yield structural 
perturbations and through co-expression with the Nav channel, how these 






 Although we have identified the residues involved in formation of the 
disulfide bridge linking Nav1.2 to the β2 and β4 subunits, a great deal more work 
remains. A toxin assay suggested that the β2 and β4 subunits sit adjacent to the 
VSDI of Nav1.2 but with our available repertoire of toxins we were unable to 
determine if the β-subunit rested between DIV and DI or DI and DII. Knowing the 
exact site would allow us to better understand the functional interface between β-
subunit and Nav channel, and to appreciate the pathogenesis of β-subunit 
mutants. Additionally, the results from this work suggest that toxins could also be 
used to determine the specific binding site of β1 and β3. The former is believed 
to sit between DIII and DIV, near the pore domains of both DI and DIV, 
suggesting that it may share an overlapping binding site with DIV-specific toxins 
[151]. Furthermore, a similar screen could be employed on the Nav channel co-
expressed with β3 in order to determine if the β-subunit shares a binding site with 
any toxins.  
 Prior research had indicated that the β-subunit is glycosylated [142, 220] 
and here we showed that mutating individual Asn residues to Gln could change 
the glycosylation pattern of β4. Before subsequent investigations into the role of 
β-subunit glycosylation can take place the nature of glycosylation in heterologous 
systems must first be reconciled. Glycosylation machinery is known to vary 
between organisms [281-283] and so first experiments must determine if the 
Xenopus system is suitable for exploring mammalian β-subunit isoforms. Once a 
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system is established, the logical steps following would involve determination of 
the extent and composition of N-linked glycosylation at each identified site and 
the effect of its removal on β-subunit folding and Nav biophysics.  
 Ultimately, the results presented in this work represent a substantial 
advance in our understanding of the Nav channel/β-subunit interaction and 
demonstrate the capable application of a number of research techniques, from 
molecular biology to electrophysiology to biochemistry. Most importantly, they 
represent several years under the tutelage of Dr. Frank Bosmans and the 







Figure 4-1: Potential location of β-subunits within the Nav channel 
signaling complex. Potential sites for β2 and β4 indicated by A and B adjacent 
to VSDI as indicated by toxin screen shown in Figure 3-14. DII highlighted in 
orange to show S5-S6 pore loop. Presumed location of β1 and β3 indicated 
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